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A B S T R A C T
Ionizing radiation is a known human carcinogen that can induce a variety of biological effects
depending on the physical nature, duration, doses and dose-rates of exposure. However, the
magnitude of health risks at low doses and dose-rates (below 100 mSv and/or 0.1 mSv min1)
remains controversial due to a lack of direct human evidence. It is anticipated that signiﬁcant
insights will emerge from the integration of epidemiological and biological research, made possible
by molecular epidemiology studies incorporating biomarkers and bioassays. A number of these have
been used to investigate exposure, effects and susceptibility to ionizing radiation, albeit often at
higher doses and dose rates, with each reﬂecting time-limited cellular or physiological alterations.
This review summarises the multidisciplinary work undertaken in the framework of the European
project DoReMi (Low Dose Research towards Multidisciplinary Integration) to identify the most
appropriate biomarkers for use in population studies. In addition to logistical and ethical
considerations for conducting large-scale epidemiological studies, we discuss the relevance of
their use for assessing the effects of low dose ionizing radiation exposure at the cellular and
physiological level. We also propose a temporal classiﬁcation of biomarkers that may be relevant for
molecular epidemiology studies which need to take into account the time elapsed since exposure.
Finally, the integration of biology with epidemiology requires careful planning and enhanced
discussions between the epidemiology, biology and dosimetry communities in order to determine
the most important questions to be addressed in light of pragmatic considerations including the
appropriate population to be investigated (occupationally, environmentally or medically exposed),
and study design. The consideration of the logistics of biological sample collection, processing and
storing and the choice of biomarker or bioassay, as well as awareness of potential confounding
factors, are also essential.
 2012 Elsevier B.V. All rights reserved.
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Ionizing radiation (IR) is a known carcinogen but the magnitude
of risk at low doses and dose-rates (i.e. below 100 mSv and/or
0.1 mSv min1) remains controversial due to a lack of direct
human evidence [1]. Epidemiological studies of radiation exposed
populations can provide evidence of risk. The most important of
these epidemiological studies for risk assessment is the Life Span
Study of the survivors of the atomic bombings of Hiroshima and
Nagasaki [2,3]. Studies of those occupationally exposed to
radiation are becoming an increasingly important source of
information on low dose/low dose-rate exposures [4,5]. However,
it is recognised that epidemiological studies can be limited in
statistical power to detect excess risk under these conditions. This
is because the population sizes required to detect excessive risk
become enormous when very small increases in risk are being
investigated. In general this dose limit is at the 50–100 mSv levelfor acute radiation exposures, though increased risks have been
observed at much lower doses for in utero exposures [6].
There is therefore a need to improve the evidence available on
which to base low dose/low dose-rate radiation risk assessment.
This is widely recognised throughout the world and several
research programmes address this issue. In Europe, the DoReMi
(Low Dose Research towards Multidisciplinary Integration)
Network of Excellence (http://www.doremi-noe.net) aims to
encourage and develop multidisciplinary approaches to low dose
risk research. DoReMi is funded by the European Commission’s
EURATOM programme for a 6 year period. In the longer term it is
envisaged that coordination and integration of European
research will be facilitated by MELODI (Multidisciplinary
European Low Dose Radiation Risk Research Initiative; http://
www.melodi-online.eu/).
Improved evidence on the magnitude of health risk of low
radiation doses is anticipated to emerge from the integration of
E. Pernot et al. / Mutation Research 751 (2012) 258–286260epidemiological and biological research through molecular/bio-
marker epidemiology and mechanistic studies. Such an integration
is by no means new but it is complex [7–10]. It will require
coordinated action and careful planning in terms of: deﬁnition of
study questions, choice of appropriate and sufﬁciently large
populations, validation of logistical and ethical aspects of sample
collection and processing, and analysis of appropriate, sensitive
and speciﬁc biomarkers over a wide range of doses.
The objective of the DoReMi network is to promote multidisci-
plinary integration and therefore offer a particularly suitable
vehicle to help develop and plan large scale molecular/biomarker
epidemiological studies. This review summarises the multidisci-
plinary work undertaken to date that has provided insight into
suitable biomarkers for use in population studies. It highlights the
outstanding needs in radiation biomarker development for
molecular epidemiological studies and the research areas, and in
particular in the -omics ﬁelds, that might provide biomarkers of
high sensitivity and speciﬁcity for radiation research. It will not
consider radiation biomarkers for clinical diagnosis, treatment
assessment and prognosis of individual cases and emphasis will be
given to research areas where potential biomarkers are already
identiﬁed. Clearly the biomarker ﬁeld is vast and this review is
based on discussions in a workshop of epidemiologists and
biologists involved in biomarker studies (most of the authors of
this review) held under the auspices of DoReMi, contact withFig. 1. Timing of radiation induced disease processes and relation with the different ty
Biomarkers of exposure are available at some point after exposure and are suitable for esti
or after exposure and can predict an increased risk of radiation effects. Biomarkers of s
individual. However, certain gene and protein expression proﬁles could vary with age. Bio
after exposure, before clinical detection of the radiation induced disease or death. Biomark
of time after exposure.additional experts and the systematic review of the published
literature on the topic using Medline and ISI Web of Knowledge. It
is hoped that this review will help reﬁne and focus research needs
for improved low dose risk estimation, a topic that is of public and
occupational health signiﬁcance.
2. General considerations on biomarkers for use in
epidemiological studies
2.1. Deﬁnitions
A biomarker has been deﬁned as ‘‘any measurement reﬂecting
an interaction between a biological system and an environmental
agent, which may be chemical, physical or biological’’ [11].
Biomarkers can be used for multiple purposes in epidemiological
investigation [12], including (1) estimation or validation of
received dose, thus improving the validity of a correlation between
exposure and biological responses; (2) investigation of individual
susceptibility and (3) early detection of a radiation induced health
effect. Multimarker approaches should be particularly useful in
epidemiological studies, both for assessing exposure–response
relationships and how these vary with individual susceptibility,
and to understand better disease mechanisms and the interplay of
different possible pathways. Conversely, carefully planned molec-
ular epidemiological studies are essential for the validation andpes of biomarkers.
mating the dose received. Biomarkers of susceptibility can be available before, during
usceptibility would be expected to remain constant throughout the lifetime of an
markers of late effects can be used to assess health effects that are present a long time
ers of persistent effects allow the assessment of radiation effects present a long period
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sensitivity as well as factors that might inﬂuence them (such as
age, smoking status or individual sensitivity).
Over the past decades, the deﬁnition and classiﬁcation of the
different types of biomarkers have varied slightly, depending on
the biomedical ﬁeld considered [11–22]. For the purpose of the
current review, we have chosen to classify biomarkers into four
categories, related to temporal parameters (Fig. 1):
 Biomarkers of exposure: these are available at some point after
exposure and are suitable for estimating the dose received.
Examples include chromosomal aberrations as discussed in
Section 4.1. They may be short-lived (e.g. dicentrics) or long-
lived (e.g. the stable translocations measured using Fluorescence
in situ hybridization [FISH] have been measured decades after
exposure in Mayak workers [23]).
 Biomarkers of susceptibility can be available before, during or after
exposure and can predict an increased risk of radiation induced
health effects. Biomarkers of susceptibility would be expected to
remain constant throughout the lifetime of an individual.
However, certain gene and protein expression proﬁles could
vary with age.
 Biomarkers of late effects can be used to assess health effects that
are present a long time after exposure, before clinical detection of
the radiation induced disease or death (the usual endpoints in
classical epidemiological studies).
 Biomarkers of persistent effects allow the assessment of radiation
effects present a long period of time after exposure.
This classiﬁcation is justiﬁed not only with respect to the timing
of processes that can be measured with these biomarkers, but also
in considering the most adequate designs and sampling proce-
dures in molecular epidemiological studies, as discussed in Section
3. It should be noted, however, that overlap exists between these
different types of biomarkers.
2.2. Characteristics of a good biomarker
Although the deﬁnitions, nature and uses of biomarkers are
multiple and rapidly evolving with the -omics technologies, some
characteristics of an ideal biomarker can be listed, including its
sensitivity and speciﬁcity, reproducibility and known variability in
the general population [11]. For use in large scale molecular
epidemiological studies, particularly in young people, an addition-
al desirable characteristic is the possibility of using non-invasive
procedures for collection of biological samples [22].
Determining if a biomarker is a good biomarker for molecular
epidemiological studies is complex because this encompasses
different concepts and will very much depend on the biological
samples that can be collected [13,14,18,24–26]. This includes
establishing the:
 validity of the assay measuring the biomarker (lack of systematic
error and minimal random error of the measurement, compared
to ‘‘the truth’’);
 validity of the marker (sensitivity, speciﬁcity, reproducibility,
and biological plausibility). In many senses this is the critical
issue with regard to the selection and/or development of
biomarkers for use in studies of exposure related health risk.
There is a need for a good understanding of what the marker is
actually measuring and to evaluate factors which may modulate
the biomarker yield such as the level of dose received and
exposure to other agents which may provoke similar biological
responses.
 suitability of the marker and assay for use in an epidemiological
study. As described in Section 3, this is related to the study design– retrospective or prospective –, logistics and timing of sample
collection and to the characteristics of the population studied,
including the dose distribution. For instance, prospective cohort
studies in which periodic contact with the study subjects is
possible would be suitable for establishing the relationship
between valid biomarkers and risk of disease because the
resulting correlations would not be affected by reverse causality
bias (e.g. disease, instead of exposure, modulating biomarker
responses).
 invasiveness and acceptability of the sample collection. Sampling
methods together with the nature and quantity of the biological
samples (urine, saliva, blood, etc.) will have practical implica-
tions for the selection of a biomarker in epidemiological studies,
particularly in children.
Those important characteristics are discussed in Section 4 for
each biomarker considered in this review.
2.3. Biomarkers following in vitro exposure
While a biomarker can be measured in human subjects or
directly in material obtained from human subjects exposed to
radiation, an important tool for measuring a subject’s biological
response to radiation exposure is via the in vitro irradiation of
biological material under deﬁned experimental conditions (Fig. 2
and Fig. 3). Such a bioassay is the method of choice for assessing,
for example, DNA repair capacity because the dose received can be
tightly controlled and responses with respect to time can be more
easily measured than in vivo. Bioassays assessing inducible
damage, repair capacity and a cell’s ability to survive can be
useful as surrogate assays to test and predict individual radiation
susceptibility. They are also particularly suitable in retrospective
studies, such as case-control studies or retrospective cohort
studies, in which it is not possible to measure biological responses
immediately after an exposure that has occurred years in the past.
Bioassays are usually performed on cell lines derived from
human subjects but primary cells can also be collected and
irradiated in vitro (e.g. rate of loss of gH2AX in lymphocytes or hair
follicles following in vitro irradiation) (Fig. 3). It should be kept in
mind, however, that the extrapolation of results from in vitro
experiments to human tissues is limited by the inherent reduced
complexity of in vitro, compared to in vivo experiments, which
reﬂect interactions between multiple tissues and biological
pathways.
3. General epidemiological considerations
Epidemiological studies in which individual information is
collected and biological samples are analyzed can be either
prospective or retrospective [27]:
 Prospective studies: In prospective cohort studies (Fig. 4) a
population with a given characteristic – for example survivors of
the atomic bombs in Japan – is identiﬁed at the time of exposure
or shortly thereafter and is followed up prospectively over time
until diagnosis of (or death from) a particular disease (cancer,
cardiovascular disease, etc.).
 Retrospective studies: They include retrospective cohort studies
deﬁned on the basis of historical records many years after
exposures (cancer survivors, miners, workers in the nuclear
industry) and case-control studies (Fig. 4). In case-control
studies, individuals with the disease of interest (cases) are
identiﬁed and compared to controls (i.e. persons which do not
have that disease and are matched to the cases with respect to
age, sex and other potentially confounding factors) selected
from the population from which the cases arise and historical
Fig. 2. Example of a retrospective study (here a case-control study nested in a cohort) to investigate susceptibility to low-dose ionizing radiation.
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Fig. 3. Collection and use of biological samples to study the effects of ionizing radiation.
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thyroid cancer in young people following the Chernobyl
accident [28]). A special type of case-control study, which
may be particularly suitable for molecular epidemiological
studies in terms of logistics and costs, is a nested case-control
study (Fig. 2 and Fig. 4). It is a case-control study in which the
cases and the controls are identiﬁed from an exposed cohort
under investigation. This is an efﬁcient study design which
allows the expensive and complex analyses of biological
samples to be conducted on a restricted number of subjects/
samples (cases of a speciﬁc disease and a subgroup of disease-
free people; for example a case-control study of childhood
leukaemia nested within a cohort of paediatric Computed
Tomography [CT] patients would require analyses on several
hundreds of subjects, rather than on hundreds of thousands).
These different types of studies imply different constraints for
the collection and use of biological samples. While in prospective
studies it may be possible to collect biological samples soon after
exposure (e.g. early Chernobyl emergency recovery workers on
whom biological dosimetry was conducted for triage, Fukushima
plant workers) and repeat the sampling later for each individual, inretrospective studies exposure has occurred a long time in the past
and in general it is not possible to measure early markers of
exposure or markers of early effects unless biological samples have
been banked before the start of the study. Retrospective studies
may allow, however, on a limited number of subjects (for example
through the conduct of nested case-control studies) the study of
radiation sensitivity through the collection of samples which could
be used in bioassays (Fig. 2).
A further important consideration in the planning of molecular
epidemiological studies is the limited (and, in record linkage
studies, non-existent) contact with study subjects which makes it
logistically difﬁcult in many studies to collect samples at different
and relevant time points from the same individual. A notable
exception are cohorts of cancer survivors who undergo active
follow-up for many years and for whom it may be possible to
collect samples which would allow the study of different types of
biomarkers over time. Worker populations are also often followed-
up at regular intervals by occupational physicians. Although
biological samples collected under such circumstances are rarely
kept, the results of standard biological analyses (cholesterol levels,
and other potential effect modiﬁers or confounders for cardiovas-
cular diseases and other diseases) and, in some countries, the
Fig. 4. Populations recruited in different types of study design.
In a cohort study, a population with a given characteristic (for example survivors of the atomic bombs in Japan) is identiﬁed at the time of exposure or shortly thereafter and
followed up prospectively over time until diagnosis (or death) from a particular disease (cancer, cardiovascular disease, etc.). In a case-control study, cases of a disease of
interest are identiﬁed and their exposure compared to that of controls (i.e. persons which do not have that disease and are as close as possible to the cases with respect to age,
sex and other factors of interest) selected from the population from which the cases arise (for example case-control studies of thyroid cancer in young people following the
Chernobyl accident). A case-control study nested in a cohort is a particular type of case-control study in which the cases and controls are drawn from a cohort under observation
(for example a childhood leukaemia case-control study, conducted within a cohort of paediatric CT patients).
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3.1. Collection and use of biological samples in epidemiological studies
A variety of biological samples can be used for biomarker
measurements in epidemiological studies, given appropriate ethics
approvals and informed consent (see Section 3.2) and do depend
on the nature of the exposure–internal vs. external. These include
blood, saliva, buccal cells, skin ﬁbroblasts, urine, faeces, hair, hair
follicle cells, and nail clippings (Fig. 3). In vivo analysis of electron
spin resonance (ESR) of tooth enamel is also possible (see Section
4.7.4). In cancer patients, tissue may also be available from biopsies
and/or surgery (generally including healthy as well as tumour
tissue). It is beyond the scope of this paper to discuss the technical
requirements for sample collection and processing, but this is an
important issue for consideration in molecular epidemiological
studies (for example the type of anticoagulant to be used for blood
collection may affect the usefulness of the sample for speciﬁc
analyses). More technical details can be found in the 2011
cytogenetic dosimetry guide from the International Atomic Energy
Agency [29].
Because of the burden imposed on study participants, collection
of samples for the purpose of a molecular epidemiological study
should be well justiﬁed, minimally invasive, pose no health risk and
interfere minimally with the participant. Blood should be collected
only when the added information cannot be obtained fromelsewhere. DNA for genotyping can be extracted for example from
saliva and from exfoliated cells collected from the mouth (buccal
cells) or urine (urothelial cells) [30,31]. The collection of saliva or
buccal cells with commercially available kits has been validated and
used in many molecular studies for extraction of DNA and more
recently, RNA [32–37]. This method presents important logistical
advantages – in particular when the study population is geographi-
cally dispersed and also because it does not require trained
personnel – and ethical and compliance advantages compared to
blood, particularly in studies involving children and/or repeated
sampling. It has to be recognised that the quantity of DNA that can be
isolated from different biological samples will vary, although recent
technological advances described below can be used to amplify DNA
from many sources. Biopsy and other tissue collection outside the
setting of surgery are rare with the exception of hair, hair follicle, toe
nails and skin punch biopsies that can be used to isolate ﬁbroblasts
and are ethically acceptable in some countries.
The development and validation of biomarkers of exposure,
susceptibility, persistent and late effects are therefore limited by
access to appropriate biological samples collected and stored
under appropriate conditions. In many situations there is only a
small window of opportunity after which the study subject may no
longer be available or conditions may have changed. In most
cohorts, moreover, multiple or repeated sample collection is not
feasible.
As discussed by Holland et al. [38], the main challenges of
molecular epidemiology are: (a) obtaining a large amount of
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evaluation of future biomarkers; and, (c) maximizing the
information that can be obtained from banked samples. Indeed
the banking of samples is, in itself, a central issue especially for
long-term studies and for future sample use in new studies.
Storage can affect the quality of the samples and determine their
future usefulness for the evaluation of different markers. For
instance samples collected at biopsy and surgery for diagnostic
purposes are usually ﬁxed in formalin and embedded in parafﬁn
before histological examination and long-term storage. This
ﬁxation process leads to structural changes in RNA, thus limiting
the usefulness of such biological material for the assessment of
RNA expression although shorter microRNAs (miRNAs) can be
successfully extracted from such samples. In recent years
techniques such as whole genome ampliﬁcation (WGA) and
multiple displacement ampliﬁcation (MDA) have proven efﬁcient
for the ampliﬁcation of small amounts of DNA, including DNA from
single cells. The ampliﬁed DNA is suitable for multiple downstream
applications, such as sequencing, short tandem repeat analysis,
array comparative genomic hybridization and methylation analy-
sis (see for instance [39,40]).
3.2. Ethical considerations
The use of biological samples raises a number of ethical issues
which in most countries are governed by law. The study design,
questionnaires and informed consent documents usually have to
be approved by institutional and/or national ethical review boards
before the start of the study. In addition, because data are collected
and stored, many countries also require approval from the agencies
that oversee data protection and freedom of information and from
the ethical review committees of all participating hospitals. These
approvals are frequently a prerequisite for applying for ﬁnancial
support of the study. In addition, if the collection of biological
material can potentially create a risk for the subject participating in
the study (e.g. the collection of blood samples), national ethical
committees also require that this is covered by appropriate
indemnity arrangements.
Informed consent has to be obtained from study participants
prior to the collection and use of biological samples and/or their
medical, social and occupational data [41]. Potential risks and
harms for the participant must be clear, as well as the fact that a
participant enters the study voluntarily with the right to withdraw.
In recent years the nature of the informed consent has changed in
many countries as it is now not just a question of the participant
acknowledging that they are aware of the potential risks associated
with giving a sample for a speciﬁc purpose at the time, but requires
a broader consent of the participant because of the rapidly
expanding biotechnological progress in sample analysis. In such
circumstances it has to be understood by the participants that they
agree to the use of their samples for unspeciﬁed assays at some
time in the future and that the material together with the data may
be stored for undeﬁned periods of time, e.g. if cell lines are
established out of subjects´ primary cells. Guidelines exist to assure
the proper and legal handling of specimen and health data [42–45].
Usually it is required that a subject’s sample and data are
completely anonymous. That means there is no link to the subject’s
name or address. If this is not possible, because a participant has
the possibility to withdraw his consent to a later time point, the
sample and the data have to be coded. For this purpose, data and
samples are usually dissociated from the personal identiﬁcation
with an independent person such as the data protection ofﬁcer of
an organization, holding the codes so that a person can be
eventually identiﬁed with their prior written informed consent.
This guarantees that people who are analyzing samples and data
are not able to link the results to a person. If a subject withdrawsfrom the study all of the stored biological materials of this
individual have to be destroyed and any analyzed data can only be
used in the future in a totally anonymous way. Another example of
when coding of data is needed is for longitudinal studies, where
sequential sampling of biological material and data occurs. For
instance the collection of health data over certain time periods may
be required to follow up the appearance of biomarkers and their
association with disease development. It is likely that such studies
will be the preferred ones in the future and will require that
participating populations accept the concept of repositories that
combine medical, genealogical and lifestyle information with
biological samples. Indeed to be effective to study the interaction
of environmental exposures such as radiation and genetic factors,
tens of thousands of people should be involved and it is likely that
national cohorts will need to be combined into European or cross-
continent cohorts (e.g. European Strategy Forum on Research
Infrastructures: European Biobanking and Biomolecular Resources
Research Infrastructure [BBMRI], launched in 2008
[www.bbmri.eu]). This possibility also means that in the informed
consent the participants agree that their stored material and data
can be given to other international researchers for analysis.
National and international data sharing and material transfer are
regulated by speciﬁc transfer agreements which govern their use
and any intellectual property generated through such research.
Because of the ethical problems arising with such an open and
wide consent including questions of autonomy to decide how
biological samples and personal data are used, several countries
have already set up or are trying to set up legislation on
‘‘biobanking’’ [46].
One major issue arising from such molecular epidemiological
research is how to inform subjects about the results of the
biological analysis carried out. With the increasing information on
genetic susceptibility to severe diseases and their corresponding
biomarkers, biological analysis can reveal information about
putative individual susceptibility to potential health risks. At the
present time many studies do not give information on individual
risks to study participants. Explaining a risk of developing perhaps
an incurable or even untreatable disease to a supposed healthy
subject could cause severe distress and even psychological
damage. In addition if the subject has been given individual risk
information, he/she might have to inform his/her life or health
insurance which could lead to discrimination in healthcare
availability and also in the workplace. In coming years these
issues will evolve as the understanding of the risks associated with
individual susceptibility and the speciﬁcity and sensitivity of
different endpoints to assess individual risk become clearer.
4. Biological classiﬁcation of ionizing radiation biomarkers
The diverse structures and functional entities in the cell are all
targets for radiation induced damages as discussed in different
sections in this review. However, which is the most relevant target
in terms of identifying and validating different types of biomarkers
after exposure to low dose and dose rate exposures still remains to
be fully determined. For instance, whilst DNA damage repair
mechanisms represent an important aspect in responses to high
doses of IR, other cellular responses such as cytokine regulation
and changes in the transcriptome, proteome, epigenome or
metabolome implicated in the global response to irradiation
may be more relevant, particularly following exposures to low
doses of radiation. This can be illustrated by the fact that most
severe cases of over response to IR amongst patients who
underwent radiotherapy showed impaired DNA damage repair,
whereas most moderate cases did not [47].
The classical approach to discover or measure biomarkers
relevant to IR exposure and responses uses a candidate approach to
E. Pernot et al. / Mutation Research 751 (2012) 258–286266evaluate endpoints based on previous hypotheses and known
biological mechanisms. The high-throughput technologies or -
omics technologies, which often depend on the use of microarrays,
are an alternative approach that tests the entire genome or the
modulations of the transcriptome, proteome, epigenome or
metabolome. Unlike hypothesis-driven research, it has the
potential to identify biomarkers of IR with no prior assumptions
about underlying biological mechanisms. This is a potent tool but
the analysis and interpretation of the data obtained remains
challenging [48].
In this review we consider a non-exhaustive list of potential
biomarkers for IR exposure and response that are implicated in
cellular or physiological mechanisms and rely on a hypothesis-
driven or an -omics approach. Keeping in mind that many
biomarkers could be classiﬁed in multiple categories (e.g. gH2AXFig. 5. Overview of the biomarkers of ionizing radiation covered in this review.
Vertical double lines represent pairs of chromosomes and horizontal double lines repr
A: acetyl group; CCR: complex chromosomal rearrangement; CNV: copy number varian
hypoxanthine-guanine phosphoribosyltransferase; M: methyl group; miRNA: microRN
oxygen species; SNP: single nucleotide polymorphism; SSB: single strand break; U: ubrepresents a protein modiﬁcation but is strongly associated with
DNA damage, 8-oxo-dG represents a nucleotide damage but is also
generated by reactive oxygen species (ROS), the phosphoproteome
is inﬂuenced by epigenetic modiﬁcations but is also implicated in
many signalling pathways), we have classiﬁed them as (a)
cytogenetic biomarkers, (b) biomarkers related to nucleotide pool
damage and DNA damage, (c) biomarkers related to germline
inherited mutations and variants, (d) biomarkers related to
induced mutations, (e) biomarkers related to transcriptional and
translational changes, (f) biomarkers related to epigenomic
modiﬁcations, and (g) other biomarkers, including biophysical
markers of exposure (Fig. 5). For certain of these, little information
is available on their usefulness for radiation molecular epidemio-
logical studies but several show potential and the purpose of this
section is to review the available information. Due to the natureesent double strands of DNA.
t; CRP: C-reactive protein; DSB: double strand break; GYPA: glycophorin A; HPRT:
A; P: phosphate group; PCC: premature chromosome condensation; ROS: reactive
iquitin; 6-TG: 6-Thioguanine; 8-oxo-DG: 8-Oxo-deoxyguanosine.
Table 1
Cytogenetic biomarkers.
Biomarkers Assays/methodology Sensitivity Speciﬁcity to IR and
confounders
Time window after
exposure during which
assays might be performed
Biological material
needed to perform
the assaysa
Dicentrics Dicentric chromosome
assay
0.1–5 Gy Almost exclusively
induced by IR
Before renewal of PBL WB: fresh;
PBMC: fresh and frozenb
Translocations Single colour FISH
G-banding
0.25–4 Gy Confounding factors:
smoking; strong age effect
Years WB: fresh;
PBMC: fresh and frozenb
CCR Multiple colour FISH Unknown High LET and heavy
ion exposure
Before renewal of PBL WB: fresh;
PBMC: fresh and frozen
PCC PCC assay combined
or not to FISH
chromosome painting
or c-banding
PCC fragments:
0.2–20 Gy
PCC rings: 1–20 Gy
IR speciﬁc to a
large extent
PCC fragments:
ideally immediately
after exposure
PCC rings: before
renewal of PBL
PBMC: fresh and frozen
Telomere length Flow cytometry
Quantitative-FISH
Southern blot
qPCR
Not yet established Not speciﬁc: modulated
by viral infection
Potential confounders:
age, oxidative stress
Not yet established WB, PBMC, cell lines:
fresh and frozen
Micronuclei Cytokinesis block
micronucleus assay
Micronucleus centromere
FISH assay for low doses
Flow cytometric detection
of DNA in reticulocytes
0.2–4 Gyc but limited
sensitivity at
doses <1 Gy.
Selective scoring after
centromere FISH:
100 mGy
Not speciﬁc: modulated
by genotoxins
Confounding factors:
age, gender
In lymphocytes:
before renewal of PBL
In reticulocytes:
not yet established
WB, PBMC: fresh
and frozenb;
Reticulocytes: fresh
CCR: complex chromosomal rearrangement; FISH: Fluorescence in situ hybridization; PBMC: Peripheral Blood Mononuclear Cell (lymphocytes, monocytes, etc.); PBL:
Peripheral blood lymphocytes (T lymphocytes for assays requiring cycling cells); PCC: premature chromosome condensation; qPCR: quantitative polymerase chain reaction;
WB: whole blood.
a Sample storage conditions listed when known.
b Frozen samples give lower yields of scorable cells.
c Dose range for photon equivalent acute whole-body exposure 24 h ago.
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separately approaches for the biological estimation of dose for
internal emitters.
4.1. Cytogenetic biomarkers
Cytogenetics focuses on the study of chromosomes, in
particular chromosomal anomalies. Several cytogenetic endpoints
are routinely used as biomarkers of exposure as they show a high
degree of speciﬁcity and sensitivity. Other cytogenetic measure-
ments might be useful as biomarkers of late effects but need to be
validated against well deﬁned outcomes/endpoints. Cytogenetic
biomarkers are summarised in Table 1.
4.1.1. Dicentrics
Dicentric chromosomes (i.e. chromosomes with two centro-
meres) are, with only very few exceptions, induced by IR. They are
stable within non-dividing cells such as lymphocytes but as the
half-life of blood lymphocytes is in the order of months/years
depending on the sub-population [29], the dicentric is the
biomarker of choice for investigating recent exposure to IR. In
general, as there are no major confounders inﬂuencing the yield
of dicentrics, its natural occurrence is very low (generally in the
order of 0.5–1/1000 cells scored). Individual dose assessment can
be achieved for homogeneous whole-body exposures to doses as
low as 100 mGy for low-linear energy transfer (LET) IR if up to
1000 cells are analyzed. However after exposure to low doses, the
calculated estimates often carry large uncertainties, mainly due
to the insufﬁcient number of cells scored. Since the dicentric
assay is very laborious, counting sufﬁciently large numbers of
cells will be a limiting factor and will limit the possibilities for
adequate dose estimation in the low dose range on an individual
level. Automated systems are under development and provide
very reproducible results but their major limitation is the
dicentric’s detection efﬁciency that remains around 50–70%
[29]. Nevertheless, automated dicentric assays are currentlybeing investigated in the framework of the European Multi-
biodose project (http://www.multibiodose.eu) that is aimed at
analysing and adapting biodosimetric tools to manage high scale
radiological casualties.
In addition to acute whole-body exposures, dose estimation for
protracted and partial-body exposure can also be achieved by
scoring dicentrics in lymphocytes. It should be noted that in order
to estimate dose, calibration curves are necessary. Although the
scoring of dicentrics is most suitable as a biomarker for external
exposures [49], it can also be informative after internal exposures
to radionuclides that disperse fairly uniformly around the body.
Isotopes of caesium and tritiated water are two such examples
[29]. Dicentric aberrations are unstable because their frequency
decreases with the turnover of peripheral blood lymphocytes.
Thus, for reliable dose assessment, dicentric aberration assays
should be performed within a few weeks of exposure. If performed
later, the precision of the assay is diminished as the dose
calculation requires the use of half-time estimates for the
disappearance of dicentrics [29].
4.1.2. Translocations
In contrast to dicentrics, translocations are chromosomal
aberrations that have been shown to persist in peripheral blood
lymphocytes for years and can thus be used as biomarkers of past
exposures [29]. This persistence reﬂects the presence of transloca-
tions in the lymphatic stem cells and is affected by many factors.
These include exposure conditions, such as dose rate and whole-
body vs. partial-body exposure. As translocations may be parts of
complex chromosomal rearrangements (CCRs) [50] that are
unstable (see Section 4.1.3), it is essential to distinguish their
origin within the cell. The cells that are scored also inﬂuence
measurements and dose calibration for translocations, as it has
been shown that the presence of unstable chromosomal aberra-
tions in the same cell reduces the frequency of translocations with
time [51]. Therefore, only cells free of any unstable chromosome
damage should be scored.
E. Pernot et al. / Mutation Research 751 (2012) 258–286268A common feature of translocations among non-exposed
subjects is the large inter-individual variation in their number,
age being the most important confounding factor [52]. Therefore,
natural occurrence and accumulation with lifespan can confound
very low dose exposure estimations. Despite the strong age-effect
for translocations, subjects of the same age may show large
variation in translocation frequencies. The reasons for the age-
dependent baseline frequency are not fully established, but some
of them may be linked with cellular mechanisms changing with
age such as DNA repair. From a number of confounders tested,
smoking has been demonstrated to increase translocation fre-
quencies in some studies, but not in others, possibly due to
variations in cigarette types or numbers smoked [53]. Other
sources of variation may include clastogenic agents in the diet or
environment, gender, ethnicity and genetic polymorphisms in
genes involved in cellular defence mechanisms. Individual dose
assessment using translocations is strongly dependent on the
personal baseline frequency of this aberration. As this information
is almost never available, the alternative is to refer to a large study
of non-exposed individuals and apply corresponding age-related
baseline frequencies in individual dose calculations [52]. Using
frequencies of unexposed subjects, it has been shown that the
minimum detectable acute dose increases linearly with age at a
rate of 1.8 mGy per year from the age of 20 up to 69 years. For
chronic exposure, the corresponding value is 15.9 mGy per year
[54].
As for dicentrics, the precision of using translocation analysis as
an exposure biomarker at doses <1 Gy would be vastly improved
by substantially increasing the number of translocations scored
per subject (e.g. n = 30) and thus increasing the number of cells
scored up to thousands of cell equivalents, in contrast to the
prevalent practise of a few hundred per individual [53]. However,
from a practical point of view, the time required for the analysis
would severely limit the use of such an approach in large molecular
epidemiological studies. FISH (or ‘‘chromosome painting’’) is
commonly used for the detection of inter-exchanges, such as
translocations and dicentrics. In studies assessing exposures to IR
that are either chronic or have occurred in the past, single (or
multiple) colour FISH together with a pancentromeric probe is
commonly applied for identiﬁcation and quantiﬁcation of two-way
or one-way translocations. Currently the assay could be semi-
automated, for instance through the use of a metaphase ﬁnder
system, but there is still a need for a fully automated image
analyser that would reliably differentiate normal cells from cells
with chromosomal aberrations [53,55].
4.1.3. Complex chromosomal rearrangements
CCR involve a minimum of three or more breaks in two or more
chromosomes [56] and can be described as a combination of
several simple aberrations, such as translocations, dicentrics, ring
chromosomes or acentric fragments. The introduction of multi-
colour FISH into cytogenetics has widened the spectrum of
aberrations amenable to detection (reciprocal translocation,
insertion, and deletions) of radiation exposure, and it has made
it possible to reﬁne the detection and deﬁnition of CCRs that were
only possible before with conventional staining (Giemsa staining
or standard methodology). CCR’s natural occurrence is very low
and its presence without exposure was almost exclusively
conﬁned to some populations and may imply a DNA repair defect.
The CCRs are unstable since they decrease with the turnover of
peripheral blood lymphocytes [57]. The presence of CCRs is
considered to be a signature for high LET and heavy ion exposure
[58,59]. There have been several reports that past irradiation can
leave a permanent signature in the genome even several years after
the exposure, as evident in plutonium workers exposed in 1949 in
the Mayak Production Association near Ozyorsk, Russia [23], NewZealand nuclear test veterans exposed in 1957–1958 [60], patients
treated with X-ray irradiation for ankylosing spondylitis [61],
Hodgkin lymphoma patients treated with chemotherapy associat-
ed to radiation therapy [62], Hiroshima atomic bomb survivors
[63,64], and Chernobyl cleanup workers [65–67]. However,
currently there is no study assessing the usefulness of this
potential biomarker after low dose exposure and further studies
are needed to investigate the effect of low-LET radiation exposure
on its occurrence. In addition, as for translocation scoring, CCR
scoring with FISH is technically demanding and without automa-
tion, it is unlikely that from a practical point of view this biomarker
could be used in large scale epidemiological studies.
4.1.4. Premature chromosome condensation (PCC)
Measurement of chromosomal aberrations requires that the
cells of interest are in mitotic phase where chromosomes are
condensed and visible. PCC techniques can induce a condensation
of the chromosomes in quiescent and cycling cells whether by
fusion with mitotic cells or by chemical treatment. In quiescent
cells the number of excess PCC fragments (>46 chromosomes for
human) are scored. In cycling cells, it is also possible to score ring
chromosomes, dicentrics and translocations if the PCC assay is
combined with FISH chromosome painting or c-banding [29,68–
72].
PCC has been reported to be most useful for assessing high dose
acute exposures to low LET radiation [73]. Dose–response data
from 0.2 to 20 Gy have been achieved for the PCC fragment assay
whereas with the PCC ring method, the sensitivity ranges from 1 to
>20 Gy [73–75]. PCC has been successfully used in some cases of
exposure, especially for problems of radioprotection and assess-
ment of doses received after medical imaging (X-ray and nuclear
medicine) [76]. When scoring excess PCC fragments, sampling and
lymphocyte isolation after treatment should be performed without
delay, otherwise repair kinetics should be taken into account [75].
4.1.5. Telomere length
Telomeres are heterochromatic domains composed of repeti-
tive DNA (TTAGGG repeats) bound to an array of specialized
proteins situated at the very end of chromosomes. The length of the
telomere repeats and the integrity of the telomere binding proteins
are both important for telomere protection. Loss of telomere
function can lead to genomic instability and cancer progression
[77] and is associated with radiation-induced genetic instability,
increased radiation sensitivity, loss of cellular viability, and
senescence [78–81]. The association between telomere length
and individual radiation sensitivity was initially based on the fact
that accelerated telomere shortening was commonly observed in
cells from patients with IR sensitive syndromes (reviewed in [82]).
Later, it was proposed that short telomeres contribute to genomic
instability in the aged progeny of irradiated cells [83–86]. It has
also been shown that telomere length modulates chromosome in
vitro radiosensitivity in healthy individuals as the group with short
telomeres presented higher frequencies of IR-induced micronuclei
(MN) when compared to the long telomeres group [87]. Moreover
telomere alterations and genomic instability are described in long-
term cultures of normal human ﬁbroblasts irradiated with X-ray
and protons [88]. The quantiﬁcation of telomere lengths in cohorts
of persons exposed to radiation shows potential as a biomarker of
risk for secondary malignancies and late complications [62].
However, further studies are needed to validate the use of this
biomarker in molecular epidemiological studies, in particular for
low-dose IR. It should also be noted that age and oxidative stress
are potential confounders and that viral infection can inﬂuence
telomere length. From a practical point of view, the automation of
the quantiﬁcation of telomere lengths has resulted in the ability to
evaluate large numbers of cells quickly and efﬁciently. Flow
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been used with considerable success [89,90]. Shortened telomeres
can also easily be detected by a PCR assay although problems of
reproducibility have been reported [91].
4.1.6. Micronuclei
MN form when intact chromosomes or fragments are not
properly segregated into daughter cell nuclei at anaphase but
instead remain in the cytoplasm after cell division. They can be
visualised as small spherical objects using any conventional DNA
dye. In comparison to most other cytogenetic techniques, MN are
far easier to score both manually and using automated microscopy
slide scanning and image analysis systems [29,92,93]. In fact, as for
the dicentric assay, one of the workpackages of the European
Multibiodose project focuses entirely on automated MN assay. As
MN form only during cell division and, like dicentrics, are lost
when cells continue to divide, the most reliable quantitative
results are achieved by blocking the cell cycle progression of PHA-
stimulated lymphocytes at the stage of cytokinesis after the ﬁrst
mitosis using cytochalasin B. Microscopic scoring of MN is then
only performed in binucleated cells. Such measurements can be
made on fresh whole blood or frozen peripheral blood lympho-
cytes; the subsequent sample preparation, scoring and analysis
procedures have been largely harmonised among biodosimetry
labs [29], and an ISO standard is in preparation.
In addition to MN scoring to assess exposure, the same samples
can also be analyzed for the nuclear division index, different modes
of cell death as well as other types of chromosomal aberrations
such as nucleoplasmic bridges – which are correlated to dicentrics
and centric rings – and nuclear buds which are associated with
gene ampliﬁcation in an approach known as the ‘Cytome Assay’
[94].
MN measured by cytokinesis-blocked micronucleus (CBMN)
assay show promise as a biomarker for individual radiosensitivity
and susceptibility to environmental carcinogens [95]. Consistent
with this notion, a recent twin study provided evidence for the high
heritability of baseline and induced MN frequencies [96].
Due to variable base levels in different individuals, the standard
CBMN assay cannot detect acute whole body doses below 200 mGy
for low-LET IR. In addition a wide range of clastogenic and
aneugenic agents (i.e. agents causing chromosome breakages and
abnormal number of chromosomes, respectively) can induce MN,
and confounding factors include age and gender. Most of this
background ‘noise’ of MN in non-exposed individuals can be
attributed to the loss of one intact copy of the X-chromosome.
Selective scoring of MN that are negative for centromere-speciﬁc
FISH signals can signiﬁcantly improve the sensitivity to a
minimum detectable acute whole body gamma-ray dose of
100 mGy for individuals [97]. First steps have been made
towards the development of an automated analysis system for
the micronucleus centromere assay [98] which would enable
large-scale studies of cohorts exposed to low-to-moderate
radiation doses. Other limitations of the CBMN assay include the
minimum delay of 3 days between sampling and ﬁrst results
becoming available, loss of the signal with lymphocyte turnover
(as discussed above for dicentrics) and its inability to detect non-
uniform exposures [97].
As an alternative to the microscopic CBMN assay in lympho-
cytes, MN can also be detected by ﬂow cytometric detection of DNA
in reticulocytes [99]. Because micronucleus-carrying reticulocytes
are normally trapped in the spleen, only a small fraction can be
detected in the blood. However, this population of recently
matured reticulocytes can be increased by immunomagnetic
enrichment or ﬂow sorting of transferrin receptor positive cells
[100]. Initial results are encouraging but more studies are needed
to assess the full potential and limitations of the reticulocytemicronucleus assay and its use as a biomarker for radiation
exposure and individual sensitivity, in particular at low doses.
4.2. Biomarkers related to nucleotide pool damage and DNA damage
IR can induce a variety of DNA damage either directly or
indirectly via ionization events produced by radiation-induced
reactive ROS. For example exposure of mammalian cells to 1 Gy of
gamma or photon radiation has been estimated to lead to 1000
single-strand breaks (SSB), 500 damaged bases, 40 double strand
breaks (DSB) and 150 DNA-protein cross-links [101]. However the
formation of these DNA lesions is not unique to IR and thus they
can not be used per se as biomarkers of exposure unless a number
of confounding factors are taken into account, including age,
syndromes associated with oxidative stress and exposure to other
genotoxins (including smoking, certain occupational settings and
chemotherapy). DNA strand breaks can be measured directly or
using surrogate endpoints such as the presence of gH2AX foci or
assays such as the comet assay. A brief outline of these techniques
is presented below but it should be noted that there is vast
literature discussing the use and limitations of such measurements
that is beyond the scope of this review. There are also a number of
methods such as HPLC-ESI-MS/MS and to a lesser extent HPLC-ECD
that are sensitive enough for measuring base lesions formed under
conditions of severe oxidative stress including exposure to IR
[102], that will also not be further discussed here. Finally, IR and
ROS can produce damage to the nucleotide pool, the measurement
of which has potential as a biomarker of exposure (see Table 5).
Biomarkers related to nucleotide pool damage and DNA damage
are summarised in Table 2.
4.2.1. DNA single/double strand breaks
Since SSB and especially DSB are highly characteristic of the
DNA lesions formed after exposure to IR, assays detecting their
formation and persistence or the individual’s ability to repair this
type of damage can be used as biomarkers for exposure or
individual radiation sensitivity.
To measure DNA SSB and/or DSB generated by IR several
techniques with different sensitivities in terms of the lesions
detected and the level of detectable DNA damage exist. These
include techniques such as alkaline or neutral ﬁlter elution
[103,104], alkaline unwinding [105,106], sucrose gradient centri-
fugation [107–109] or pulsed ﬁeld gel electrophoresis [110–113].
However the utility of such techniques for molecular epidemio-
logical studies investigating low doses effects is limited as none
can be used to investigate DNA damage after exposures to doses
under 2 Gy and at the single cell level.
The comet assay is a relatively easy, quick and automatable test
to detect direct DNA-damage at the single cell level and with a
higher sensitivity compared to methods described above [114]. Its
main advantage is the requirement of only minimal numbers of
cells (10.000) or volumes of whole blood (10 ml) [115]. It has
been widely used to measure both in vitro and in vivo DNA damage
and repair following exposure of mammalian cells to various
genotoxic agents including some chemicals, IR and non-IR [116–
119]. The assay can be performed in neutral or in alkaline
conditions. Both methods detect SSB and DSB however the alkaline
assay is often used to detect SSB and alkali-labile sites whereas the
neutral comet assay is often used to detect DSBs, although it has to
be noted that this variant of the comet assay lacks sensitivity and
speciﬁcity. With the alkaline comet assay an irradiation dose range
from 100 mGy to 8 Gy can be investigated as well as DNA repair
capacity. Because it can be automated, the assay is highly suitable
for a screening assay in human populations although some
important criteria need to be taken into consideration: (a) the
speciﬁcity for radiation exposure is low, since oxidative stress in
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inter-experimental variability is very high in the test system, so the
test has to be performed under highly standardized conditions
with an automated analyses and the inclusion of reference samples
so that comparisons can be made over-time [120]. In addition to
being used as an endpoint to assess DNA damage levels, the comet
assay can be used as a bioassay for instance to evaluate DNA repair
capacity. Using such an approach, biological samples are irradiated
in vitro and the level of persisting DNA damage with time used as a
biomarker of susceptibility [121]. The results from such assays
need to be interpreted with caution as a number of confounding
factors including age of the subject, smoking and diet have been
reported.
4.2.2. gH2AX
The phosphorylation of the histone variant H2AX at the
site of DNA DSBs lead to the formation and accumulation of
gH2AX foci in the cell nucleus within a few minutes of DNA
damage. The maximum yield of foci is detected within 30–
60 min after irradiation, depending on the dose, and after this,
the number of foci usually decreases to baseline level within
days [47,75]. The measurement of gH2AX foci could be used as a
direct endpoint assessing the formation of damage and therefore
as a biomarker of exposure, whereas its persistence with time in
irradiated samples can be used to evaluate DNA repair capacity
and thus as a biomarker of susceptibility (see also [47] for recent
review).
Several studies on patients medically exposed to low dose
radiation have shown that the gH2AX assay is very sensitive, and
that foci after doses below 20–10 mGy can be detected. A study on
patients with differentiated thyroid carcinoma who underwent
131I therapy showed that exposure to radionuclide incorporation
can be detected by gH2AX assay in mononuclear peripheral blood
leukocytes after absorbed doses to the blood below 20 mGy [122].
Another study on patients who underwent angiographic proce-
dures and received from 2.2 to 99.9 mGy to blood has concluded on
the reliability and sensitivity of gH2AX immunoﬂuorescence
microscopy [123]. Studies investigating gH2AX foci in blood
samples of CT scanned patients before and after the CT scan, have
shown that gH2AX focus induction and loss are sensitive enough to
be used as biologic dosimeters [124,125]. However, extensive use
of the assay as a biomarker of exposure directly in biological
samples obtained from a study subject is regarded as limited due to
the fast decline of the signal as well as variation of foci frequencies
between individuals.
Despite these limitations, if samples can be obtained in
appropriate time windows, the gH2AX assay has potential to
reveal low dose hypersensitivity [126]. Lo¨brich et al. have
investigated loss of gH2AX foci in lymphocytes of CT scanned
patients and have demonstrated that the loss of gH2AX foci
correlated with DSB repair [124]. Interestingly, one radiosensitive
patient presented elevated residual foci after CT, suggesting an
impaired DNA repair. The kinetics of gH2AX foci loss might thus be
used as a biomarker of susceptibility in in vivo or in vitro studies.
However, as discussed above, due to the fast decline of the signal
after exposure, in vitro irradiation of subject’s cells to detect a loss
in gH2AX foci might be more feasible in a large scale epidemiologi-
cal study.
When considering gH2AX foci frequency or foci loss as
potential biomarkers of exposure or susceptibility, it should be
kept in mind that previous studies have provided evidence that at
very low doses (1.2–10 mGy), the loss of foci in irradiated mice or
nondividing primary human ﬁbroblasts is impaired over several
days compared to higher dose exposure [127,128]. Therefore, the
use of gH2AX foci loss as a biomarker of susceptibility in studies
investigating the effects of less than 10 mGy might not be suitablebecause the kinetics of foci loss will be difﬁcult to establish. It
should be also noted that a similar level of persistent radiation
induced gH2AX foci, depending on radiation quality (X rays vs. g-
rays) and types of sample (whole blood vs. isolated lymphocytes),
was reported after exposure to 5 and 200 mGy [264]. Regarding the
use of gH2AX foci frequency as a biomarker of very low dose
exposure, the persistence of the foci might be an opportunity to
increase the time frame of sampling and testing after irradiation
and also to discriminate between irradiated and non irradiated
cells.
Optimization of gH2AX foci analysis according to cell cycle
phases and its limitations has been reviewed recently elsewhere
[129]. Automation may improve the possibilities to apply the
technique as a biomarker in large scale accidents and molecular
epidemiological studies to investigate radiation sensitivity. There
are two ways to automate the assay: (a) ﬂow cytometric analysis,
and (b) automated microscopic analysis. Flow cytometric analysis
has the disadvantage that only total ﬂuorescence instead of single
foci are analyzed. As mentioned above for the dicentric assay and
the MN assay, the automation of gH2AX assay for rapid triage in
case of mass casualty scenario is one of the topics of interest in the
European Multibiodose project. Although there already exist some
publications that have tested or used automated assays [130–132],
large scale molecular epidemiological studies have not been
performed using the assay so far.
The possibility of using hair bulbs for gH2AX foci assays is
highly interesting in the context of an epidemiological study
because the collection of such biological samples is less invasive for
the subjects than blood or tissue collection. Although such an assay
has not yet been reported in humans for low doses, a study in non
human-primates exposed to high doses (1–8.5 Gy) showed
promising results [133]. The slower rate of gH2AX foci loss in
hair bulbs compared to lymphocytes reported in this study could
also be an opportunity to increase the time frame of sampling and
testing after irradiation. Finally, it should be noted that the
measurement of gH2AX foci in eyebrow hair follicles was used in a
pharmacodynamics study assessing the activity of PARP Inhibitors
[134].
4.2.3. Extracellular 8-oxo-dG
In the last few years attention has been drawn to the nucleotide
pool as a target of IR. It has been suggested that extracellular 8-
oxo-dG primarily originates from the sanitization process of 8-oxo-
dGTP, thus the yields of extracellular 8-oxo-dG may serve as a
biomarker of the intracellular oxidative stress (see also Section
4.7.1 on ROS) [135–137]. The mechanism(s) of radiation induced
nucleotide pool damage are not well understood, dose–response
relations suggest that in the low dose region (1–100 mGy)
radiation will trigger a stress response reaction leading to an
endogenous formation of ROS that is the dominating cause of 8-
oxo-dGTP production [135–137]. The dose–response relations are
not linear and saturates for doses in the 0.1–1 Gy range. Regarding
radiation-induced endogenous formation of ROS, mechanistic
studies in cellular model systems have shown that it is transient
with a time span over a few hours.
In parallel with the formation of 8-oxo-dGTP, the levels of the
nucleotide pool sanitizing enzyme with 8-oxo-dGTPase activity
(hMTH1) were increased following exposure to low dose radiation
suggesting that subsequent ROS production will trigger the
activation of cellular defence systems against oxidative stress
[136]. Increased serum levels of 8-oxo-dG have also been
suggested to correlate with inﬂammatory responses – that are
known to generate ROS – in a group of haemodialysis patients
[138]. Thus although extracellular 8-oxo-dG may be used as a
biomarker of oxidative stress it lacks the speciﬁcity for a biomarker
of exposure to IR.
Table 2
Biomarkers related to DNA damage and nucleotide pool damage.
Biomarkers Assays/methodology Sensitivity Speciﬁcity to IR and
confounders
Time window after
exposure during which
assays might be performed
Biological material needed
to perform the assaysa
SSB/DSB Comet assay (alkaline
Single Cell Gel
Electrophoresis assay)
0.1–8 Gy Not speciﬁc: modulated
by several mutagens and
oxidative stress
Confounding factors: age,
smoking, diet
Minutes to days
post-irradiation
WB: fresh
PBMC: fresh and frozen;
Fibroblasts: fresh and frozen;
Buccal cells: fresh
g-H2AX Immunoﬂuorescence staining
Flow cytometry
High throughput
electrochemiluminescent
platform
0.01–8 Gy Not speciﬁc: also formed
in response to UV and
other genotoxins
Minutes to days
post-irradiation
PBMC, fresh and frozen;
Fibroblasts: fresh and frozen
Buccal cells: fresh
Tissues: frozen and FFPE
Hair follicle bulbb: fresh;
Hair follicle bulge stem
cellsc: fresh
Extracellular
8-oxo-dG
HPLC-ECD Modiﬁed ELISA 1–100 mGy
Saturation for
doses between
0.1 and 1 Gy
Not speciﬁc: also formed
by endogenous oxidative stress
Confounding factors: unknown
1–2 h post irradiation WB: fresh; PBMC: fresh;
Serum: fresh and frozen;
Cell lines, Saliva, Urine
DSB: Double Strand Break; ELISA: Enzyme-linked Immunosorbent Assay; FFPE: Formalin-Fixed Parafﬁn-Embedded; HPLC-ECD: High Performance Liquid Chromatography
coupled to Electrochemical Detection; PBMC: Peripheral Blood Mononuclear Cell (lymphocyte, monocytes, etc.); SSB: Single Strand Break; WB: whole blood.
a Sample storage conditions listed when known.
b Reported for non-human primates.
c Reported for mice [140].
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search for biomarkers of individual susceptibility. It has been
shown that the urinary levels of 8-oxo-dG, produced during
radiotherapy, differed signiﬁcantly between a cohort of patients
that developed severe side effects when treated for breast
cancer compared to a group that showed no side effects [139].
This observation needs to be validated in a larger cohort before
extra cellular 8-oxo-dG can be used as a biomarker of
susceptibility. Further studies are also needed to investigate if
such differences are seen under conditions of low acute and
chronic exposures and to determine the impact of confounding
factors such as age, smoking, diet and medical conditions, e.g.
autoimmune disease and viral infections, that might alter levels
of oxidative stress.
4.3. Biomarkers related to germline inherited mutations/variants
Biomarkers related to germline inherited mutations or variants
are summarised in Table 3.Table 3
Biomarkers related to inherited and induced mutations.
Biomarkers Assays/methodology Sensitivity Speciﬁcity t
confounder
SNPs and inherited
gene mutations
Various candidate gene
approaches
SNP arrays/GWAS
NGS (potentially)
Unknown Not speciﬁc
Confounder
CNV and CNA CGH, array CGH
FISH
NGS
Unknown Not speciﬁc
Confounder
CNA: age
CNV: unk
GYPA (in heterozygous
MN blood group only)
Flow cytometer >1 Gy Not speciﬁc
exposure to
genotoxins
HPRT Thioguanine selective
cloning assay
PCR
>90 mGy Not speciﬁc
exposure to
genotoxins
CGH: comparative genomic hybridization; CNA: copy number alteration; CNV: copy num
hybridization; GYPA: glycophorin A; GWAS: genome-wide association study; HPRT: hyp
PBMC: peripheral blood mononuclear cell (lymphocyte, monocytes, etc.); PCR: polyme
a Sample storage conditions listed when known.4.3.1. Single Nucleotide Polymorphisms (SNP) and inherited gene
mutations
It is well accepted that individual heterogeneity in responses to
radiation exist yet the genetic determinants and the molecular
mechanisms of altered sensitivity and even resistance remain
poorly understood. The deleterious clinical consequences of
inherited defects in DNA repair systems are apparent from several
human syndromes. Examples are individuals carrying mutations in
the Ataxia Telangiectasia Mutated (ATM) gene, which is essential
for DNA DSB recognition and the following damage response
cascade activation. These individuals have an increased risk to
develop cancer and when treated during radiation therapy often
develop severe side effects of the normal tissue. However such
deleterious mutations are too rare in the general population to be
of a major public health impact in terms of responses to radiation.
Radiation sensitivity can be regarded as a quantitative complex
phenotype or trait due to the combined effect of many more
frequently found susceptibility sequence variants, such as SNPs –
i.e. a variation at a single position in a DNA sequence present ino IR and
s
Time window after
exposure during
which assays might
be performed
Biological material needed
to perform the assaysa
s unknown
Not time dependent WB: fresh, frozen, dried;
PBMC: fresh and frozen;
Fibroblasts: fresh and frozen;
Tissue: fresh, frozen, FFPE
s:
;
nown
CNV: Not time dependent
CNA: Not yet established
WB: fresh, frozen, dried;
Tissue: fresh, frozen, FFPE
: formed after
 other
Years WB: fresh;
Erythrocytes
: formed after
 other
Months PBMC: fresh and frozen
ber variant; FFPE: formalin-ﬁxed and parafﬁn-embedded; FISH: ﬂuorescence in situ
oxanthine-guanine phosphoribosyl transferase; NGS: next generation sequencing;
rase chain reaction; SNP: single nucleotide polymorphism; WB: whole blood.
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factors. A comprehensive search for the genetic risk factors for
radiation sensitivity would ideally examine all the genetic
differences in a large number of affected individuals and controls.
It may eventually become feasible to accomplish this by complete
genome sequencing (using next generation sequencing [NGS] for
instance) but to date attempts to identify genetic variants
associated with radiation sensitivity have almost exclusively used
a candidate gene approach assessing the frequency of common
variants in cases and controls and more recently using genome
wide association studies (GWAS). GWAS compare arrays of SNPs
from cases and controls in an attempt to identify functional DNA-
sequence variants that inﬂuence radiation sensitivity. One limita-
tion of GWAS compared to NGS is the fact that only common
genetic variants are investigated whereas with NGS, rare variants
can also be identiﬁed. Such studies have often been carried out in a
clinical setting where for instance early and late normal tissue
reactions to radiotherapy toxicity can be well documented [141–
143]. Many of the recent genetic association studies have focused
on identifying effects of SNPs in candidate genes, among which
DNA repair and cell cycle control genes have been extensively
studied because of their critical role in maintaining genome
integrity. SNPs in genes involved in proﬁbrotic and inﬂammatory
cytokines, endogenous antioxidants, general metabolism and
homeostasis may be of particular relevance in situations where
exposure is to low doses of radiation which may generate elevated
levels of oxidative stress. A potentially interesting genome to
characterise in terms of sequence variants is that of the
mitochondria, as well as the genes encoding other proteins
associated with mitochondrial function, which play a key role in
the endogenous control of ROS in cells.
Many of the SNP association studies have often yielded
conﬂicting results—see for instance a critical review of the
association studies between SNPs in the Transforming Growth
Factor b (TGFb) gene and clinical radiation sensitivity [143]. As
highlighted in this review many studies are very heterogeneous in
terms of patient selection, tumour site, radiotherapy technique and
normal tissue endpoints and are small in size so are severely
underpowered from a statistical point of view to detect an
association between the presence of a speciﬁc allele at a SNP and
the risk of developing complications linked to treatment. In addition
many studies investigated several SNPs and a number of different
endpoints yet rarely have taken steps to correct for multiple testing
which leads to a high risk of false positives by chance.
The need for large populations with well documented dosime-
try and biological samples that can be used for the extraction of
DNA is possible to establish in the medical setting and has led to
the establishment of a Radiogenomics Consortium [144]. This
Consortium aims to develop an assay capable of predicting which
cancer patients are most likely to develop radiation injuries
resulting from treatment with a standard radiotherapy protocol
and to identify genes possessing SNPs associated with the
development of radiation-induced adverse effects ranging from
early to late and even second cancers. Such studies will be highly
relevant for other radiation exposed cohorts which could be used
to identify and validate genetic biomarkers using candidate gene
approaches and whole genome association studies.
4.3.2. Copy number variants (CNV) and alterations (CNA)
Advances in technologies that allow whole genomes to be
screened for variations such as high-resolution SNP arrays have
made it possible to identify CNVs. These structural variants that
arise from deletions (loss) or duplications (gain), can include entire
genes or regions of transcribed sequence, or, can comprise only
nontranscribed sequences. The role of CNVs in cancer has only
emerged in the last few years when constitutional CNVs wasobserved in the Li-Fraumeni cancer susceptibility syndrome and in
neuroblastoma [145]. The impact of CNV on biological approaches
and in particular after radiation exposures is also a research ﬁeld
that has been very little studied either in vivo or in vitro. A recent
publication has shown that mouse ATM/CHK2/p53 activity was
very dependent on ATM, Trp53 (p53) and Chek2 (CHK2) copy
number before and after in vitro ionizing irradiation and that the
relationship between gene copy number and transcriptional
induction after radiation was linear for p21 and Puma and
correlated well with cancer incidence in p53 variant mice [146]
(see also Section 4.5.1). Clearly certain CNV show associations with
radiation responses and by extrapolation may be exploitable as
biomarkers of variation in responses. However, their usefulness in
molecular epidemiological studies remains to be established.
Acquired CNVs (or copy number alterations [CNA]) have also
been found in certain tumours. For example IQGAP1 CNA is
associated with the invasiveness of thyroid cancer and may
represent a novel prognostic marker and therapeutic target for this
cancer [147]. In addition, a study conducted on young patients
with papillary thyroid carcinoma exposed to an estimated average
dose of 150 mGy after the Chernobyl accident showed an
ampliﬁcation of the region 7q11.22–11.23 in a subgroup of
exposed patients, and could potentially represent a biomarker of
exposure, although possibly limited to certain cases or dose ranges
[148]. However whether the presence of speciﬁc CNAs reﬂects the
tumour aetiology remains to be examined. Other biomarkers
related to mutations induced by IR are discussed in the following
section.
4.4. Biomarkers related to induced mutations
Two somatic mutation assays, the Glycophorin A (GYPA) and
hypoxanthine-guanine-phosphoribosyl transferase gene (HPRT)
mutation assays (described below and see also [75] for recent
review), are frequently used in the biodosimetry ﬁeld. However
whether radiation induced tumours have a speciﬁc mutation
proﬁle remains to be established. As noted in Section 4.3.2, a recent
study has identiﬁed a potential genetic signature of radiation-
induced thyroid tumours [148]. In another study assessing the
mutational pattern of a reporter gene in mouse ﬁbroblasts upon
fractionated IR exposure, a high proportion of T:A ! G:C transver-
sions was observed [149]. Some hints have also been obtained from
medical settings. For instance in one study investigating the TP53
mutation pattern in radiation-induced sarcomas, a high proportion
(58%) of sarcomas showed a somatic inactivating mutation for one
allele of TP53, systematically associated with a loss of the other
allele, and a high frequency of short deletions (52% of the
mutations) [150]. In addition, the lack of mutations in CpG
dinucleotides together with the presence of recurrent mutation
sites at codons 135 and 237 also seemed to be speciﬁc for radiation
tumorigenesis. However these observations are limited in many
respects and clearly need to be extended to examine more tumour
types and other tumour sites.
Biomarkers related to induced mutations are summarised in
Table 3.
4.4.1. Glycophorin A in MN blood group heterozygotes
GYPA is a glycoprotein present on the surface of erythrocytes.
The gene has two allelic forms, gpaM and gpaN that give rise to
proteins that differ in only two amino acid residues. Alterations at
the GYPA locus in erythrocyte progenitor cells produce variant red
cells that have lost the expression of one of the alleles. This allele
loss can be detected using ﬂuorescent labelled antibodies against
the M and N forms of GYPA in individuals heterozygous for the MN
blood type (gpaM/N) (50% of the human population is heterozy-
gous with respect to the MN blood group). Thus the GYPA assay
Table 4
Biomarkers related to transcriptional and translational changes.
Biomarkers Assays/methodology Sensitivity Speciﬁcity to IR
and confounders
Time window after
exposure during
which assays might
be performed
Biological material
needed to perform
the assaysa
ATM/CHK2/p53 pathway Various candidate gene
approaches, e.g. TAQMAN, qPCR
Unknown Not speciﬁc Probably hours to days PBMC, WB, cell lines
Changes in RNA levels
identiﬁed by
transcriptomics
Microarrays, qPCR, NanostringTM
NGS (potentially)
Unknown Unknown at
present time
1–3 days PBMC, WB, cell lines
Serum amylase Serum amylase assays >1 Gy Not speciﬁc 24 h after exposure Serum
CRP ELISA >1 Gy Not speciﬁc: modulated
by levels of inﬂammation
Blood: Years
Saliva: up to 8 h
Serum and saliva with in
vivo exposure only.
Cytokines ELISA >1.2 mGy Not speciﬁc Within 24 h PBMC: fresh; serum
Proteins identiﬁed
by proteomics
NanoHPLC-LC-MS/MS
SELDI-TOF-MS
Good to
very good
Unknown at present
time/remains to be
fully established
10 min–40 weeksb
after exposure with
doses varying from
0.2 to 16 Gy
Serum: frozen;
Primary cells and cell lines;
Tissue: frozen
2DE/2D-DIGE;
MALDI-TOF/TOF;
Western blot;
Enzymatic assays;
Tissue arrays
Moderate to
very good
Unknown at present
time/remains to be
fully established
10 min–40 weeksb
after exposure with
doses varying from
0.2 to 16 Gy
Serum/plasma: frozen;
Primary cells and cell lines;
Tissue: frozen
CRP: C-reactive protein; ELISA: enzyme-linked immunosorbent assay; HPLC-LC-MS: high-performance liquid chromatography-mass spectrometry; MALDI-TOF: matrix-
assisted laser desorption/ionization-time of ﬂight; NGS: next generation sequencing; PBMC: peripheral blood mononuclear cell (lymphocyte, monocytes, etc.); qPCR:
quantitative polymerase chain reaction; SELDI-TOF-MS: surface enhanced laser desorption/ionization time-of-ﬂight mass spectrometry; WB: whole blood; 2DE/2D-DIGE:
two-dimensional protein gel electrophoresis/two-dimensional difference gel electrophoresis.
a Sample storage conditions listed when known.
b For mice. For humans: possibly more than 60 years.
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allelic form, measuring the hemizygous (M/0 or N/0) and the
homozygous (M/M or N/N generated by mitotic recombination,
gene conversion, etc.) phenotype cells with the help of a ﬂow
cytometer [151]. The frequency of GYPA variants has been
investigated in several studies on individuals exposed to IR.
Dose-dependent increase in mutation frequency and long term
persistence (years) has been observed in subjects exposed to high
doses (>1 Gy), such as A-bomb survivors and radiation accident
victims. However, the assay is not able to detect exposure to low
doses [75]. In addition, control populations show considerable
variability of the variant frequency. Although the GYPA assay has
many advantageous features such as low cost and speed, and is
relatively unaffected by environmental factors, it lacks the
possibility of in vitro dose calibration and is applicable to only
half of any study population [152].
4.4.2. Hypoxanthine-guanine phosphoribosyl transferase gene
Hypoxanthine-guanine phosphoribosyl transferase (HPRTase)
is a protein implicated in the salvage of adenines and guanines
from degraded DNA. Mutations in the HPRT gene after irradiation
can be easily detected in cultivated cells by adding the toxic
nucleoside analog 6-thioguanine (6-TG) because, unlike wild type
cells, mutated cells are able to survive in this otherwise toxic
medium. The HPRT somatic mutation assay has been frequently
used to investigate the mutagenic effects of IR in populations
occupationally or environmentally exposed to low dose radiation
[75]. A study on Russian Chernobyl Clean-up workers aimed at
investigating HPRT mutation in lymphocytes nine years after
exposure observed that HPRT mutant frequency was sensitive
enough to assess past exposure to low doses [153]. However,
because it declines over time, this biomarker was not considered as
a suitable retrospective biodosimeter (stable for months) [75].
More recently, HPRT has been used to investigate in vitro the
adaptive response of lymphoblastoid cell lines primed with low
doses of X-rays or heavy-ion radiation [154,155]. The mutation
frequency of cells primed with low doses of X-rays (20–100 mGy)
was reported to be similar to the mutation frequency of the nonexposed cells, whereas for cells primed with low doses of heavy ion
radiation (10 mGy), the differences were more marked, depending
on the cell line. In the framework of a large scale epidemiological
study, the use of HPRT mutations as a biomarker would be strongly
limited by the technical requirements and the time necessary to
select the mutants.
4.5. Biomarkers related to transcriptional and translational changes
Biomarkers related to transcriptional and translational changes
are summarised in Table 4.
4.5.1. Biomarkers related to changes in RNA levels
While a wide variety of transcriptional responses to IR have been
described, the relationship of these responses to health is rarely
clear. In most cases, gene expression proﬁling has been performed
after a short time following exposure. Several studies have been
published that indicate that microarray based analysis of early
transcriptional responses may predict early or late developing
adverse normal tissue reactions to radiotherapy [156,157]. Further-
more, simple quantitative real-time PCR assays hold some promise
as being predictive for normal tissue reactions [158].
With the advent of microarray technology during the late 1990s
it soon became possible to analyze the mRNA expression of all
known genes simultaneously. Later, microarrays that cover all
known exons were developed, providing increased accuracy but
also allowing analysis of transcript and splice variation. Nowadays,
more and more high-throughput studies are using NGS technology
to sequence entire transcriptomes (RNAseq). Since the costs of
these technologies are dropping rapidly, it is expected that
microarrays will become obsolete for gene expression analysis
in the near future. In addition, some comparative studies suggest
that quantitative PCR and direct molecule counting methods such
as NanostringTM hold advantages compared to microarrays [159].
Still, the use of microarray technology has provided signiﬁcant
advantages in the search for mRNA biomarkers of radiation
exposure as well as for the understanding of the biological
pathways that are involved in the radiation response.
E. Pernot et al. / Mutation Research 751 (2012) 258–2862744.5.1.1. ATM/CHK2/p53 pathway. Several examples of potential
candidate approach biomarkers of IR can be found among the
transcripts involved in the ATM/CHK2/p53 pathway (also dis-
cussed in Section 4.3.2). ATM is a kinase which is activated by DSBs
and which phosphorylates and activates p53 directly or via the
phosphorylation of the kinase CHK2. Many of the transcriptional
responses to IR are p53 dependent and p53 is known to be a key
tumour susceptibility gene. Assays using human blood and cells
have suggested that transcriptional assessment of the ATM/CHK2/
p53 pathway function in vitro could serve as a biomarker of cancer
risk [146] but a larger validation study is required and there is a
need to evaluate confounding factors [160]. Moreover, the ATM/
CHK2/p53 pathway is an early responsive-genes mechanism able
to predict exposure to radiation after few hours to few days, but not
long time after exposure such as months or years.
One of the earliest microarrays studies investigating the effect
of low to moderate doses of g-rays (0.2–2 Gy) found a dose-
dependent induction of a number of genes in isolated human
peripheral blood lymphocytes up to three days after irradiation
[161]. Most of these genes were involved in p53-regulated
pathways such as DNA damage repair, cell cycle arrest and
apoptosis. However, the effect of radiation was much less
pronounced at the later time points, indicating a decay of the
DNA damage signal. Since then, several other studies have
conﬁrmed these ﬁndings often using different methodologies
(different microarray platforms, different doses, radiation quality,
or cell types) and although they often found different genes to be
differentially expressed after irradiation, all of them found a p53-
regulated response which was attenuated with time [162–164].
This indicates that, at least at early time points (<24 h), the p53-
regulated response is pivotal providing several possible biomark-
ers (e.g. CDKN1A, DDB2, CCNG1, PCNA, TNFRSF10B, GADD45A,. . .)
for early exposure to a large range of radiation doses.
Over the past few years, gene expression proﬁles, obtained
using microarray technology, have also been used for biodosimetry
purposes. Most of these studies used blood cells (peripheral blood
mononuclear cells, whole blood, cultured lymphocytes) for
radiation doses between 0.5 and 10 Gy, over a time period
between 4 and 24 h. Again, from these studies it is evident that
genes involved in p53-regulated pathways are the best suited
predictors of radiation exposure [160,164–169]. Whether this
would also be the case for other cell types or tissues, remains to be
investigated.
Thus, it seems that changes in gene expression of certain genes
are very well suited to estimate radiation exposure, potentially
providing several advantages over the more classical cytogenetic
assays which are time consuming and labour intensive. First, the
expression analysis of limited numbers of genes is easy to perform,
quick, and cheap. Second, these assays need only a limited amount
of material (blood, RNA) as shown by a recent study in which a
biodosimetry device was used to analyze gene expression from
small blood volumes (30 ml) [165]. However, in the context of an
epidemiological study, an important disadvantage is that the
effects on gene expression seem to be short-lived and whether
changes that are speciﬁc to radiation will be identiﬁed remains to
be established. Thus, whether changes in gene expression may be
suited for dose estimation years after the exposure needs further
investigation although samples stored appropriately soon after
exposure could be investigated at later times.
Expression proﬁling has also been used to try and identify
ﬁnger-prints of radiation induced cancers in particular as they
often have no speciﬁc histological characteristics. Under such
circumstance an expression proﬁle that could be used to conﬁrm
the aetiology of a tumour would be an enormous beneﬁt to
epidemiological studies. Recent publications have suggested
that gene expression proﬁles can discriminate sporadic frompost-radiotherapy-induced thyroid carcinomas [170] and sarco-
mas [171]. The validation and the assessment of the robustness of
these molecular markers that could represent a radiation-
induction signature is essential and could help identify the speciﬁc
molecular pathways deregulated in radiation-induced cancers and
lead to the development of new biomarkers of exposure and
susceptibility.
4.5.2. Biomarkers related to changes in protein levels
Different organs respond to radiation by altering the level of
protein expression and their post-translational modiﬁcation
status. Therefore, it is reasonable to believe that protein expression
proﬁling can be used to successfully ﬁnd radiation-associated
protein biomarkers in biological samples such as urine, blood/
serum or even tissue. The usage of tissue samples has been limited
mostly to radiation-induced cancers. The primary advantage of
using tissue is that protein expression is tissue-speciﬁc and some
of the biomarkers will be maximally expressed in the targeted
tissue. The obvious primary disadvantage is the difﬁculty in
obtaining tissue specimens by biopsy or autopsy. In contrast,
protein-rich samples of biological ﬂuids – such as serum, urine or
saliva – can be collected in a non-invasive or semi-invasive
manner, and quantiﬁcation of radiation-induced protein expres-
sion can be automated using high-throughput proteomic technol-
ogies. In addition, both pre-separation methods and mass
spectrometers have seen remarkable and consistent improve-
ments over the past decade [172].
However, the discovery of radiation-associated protein bio-
markers remains an enormous challenge within radiobiological
research because of the time- and dose-dependent variation of
protein expression. Animal and cellular studies have been used as a
tool to identify potential biomarkers that then may be tested in
molecular epidemiological studies [173–177]. Marchetti et al.
conducted a literature review of candidate protein biomarkers for
individual radiation biodosimetry of exposure to IR [178]. The
study included human, animal and cellular studies using in vivo
and in vitro irradiation. All identiﬁed radiation-responsive
proteins, 261 in total, including 173 human proteins, were
tabulated and assigned to nine priority groups. This method
resulted in a proposed panel of 20 candidate protein biomarkers for
different doses and time points after exposure. Since the study by
Marchetti (2006) some new data concerning radiation-induced
changes in different proteomes have been published. Concentrat-
ing only on studies with human material we summarised the
recent studies, adding the human data from Marchetti et al.; the
radiation-responsive proteins identiﬁed in these studies are shown
in Supplementary Data A.
4.5.2.1. Amylase, Flt3-ligand and C-reactive protein (CRP). So far, the
changes in the level of only two proteins have been used as
bioindicators for radiation exposure: the amylase that indicates
radiation-induced damage of the parotid gland [179,180], and Flt3-
ligand, a hematopoietic cytokine indicating damage of the bone
marrow [181]. Both are relatively easy to measure from serum/
plasma using a clinical blood chemistry analyser or commercial
sandwich enzyme-linked immunosorbent assay (ELISA), respec-
tively. However, analyzed separately these biomarkers are neither
speciﬁc nor sensitive enough to estimate the received dose,
especially if the time from the exposure exceeds 48 h.
The variation in the level of CRP, a protein secreted by
hepatocytes in response to inﬂammation, provides an accurate
estimation of the level of inﬂammation, but it is not speciﬁc to
radiation exposure or a particular disease; for instance, it is
modulated in case of cancer, rheumatoid arthritis, cardiovascular
diseases, or upon high doses of IR. An epidemiological study
conducted in the A-bomb survivors cohort 50 years after the
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level of CRP per Gy in persons exposed [182]. However in this
study, the frequency of persons exposed to low dose radiation was
not detailed (medium–low dose group: 0.005–1.5 Gy, mean  SD:
0.66 Gy  0.45, n = 164). In the context of an epidemiological study, it
is interesting to note that CRP can be measured by high-sensitivity
ELISA in saliva, a less invasive method than venipuncture [183].
However, this assay has still to be validated, in particular for low
concentrations of CRP.
4.5.2.2. Changes in protein levels identiﬁed by proteomics. Proteomic
tools combined with statistical and bioinformatics methods are
able to discriminate several classes of samples, such as non-
exposed and exposed, based on a few variables. In the classical
gel-based proteomic analysis such as two-dimensional differential
in-gel electrophoresis (2D-DIGE) protein quantiﬁcation follows
after a separation based on the charge and molecular mass.
Proteins labelled with ﬂuorescent dyes (Cy2, Cy3, Cy5) are
analyzed in a laser-activated ﬂuorescence scanner. Coupled with
mass spectrometry this method is able to ﬁnd radiation-induced
alterations in protein expression levels and/or post-translational
modiﬁcations. The gel-free tandem mass spectrometry (LC-MS/
MS) method is based on the peptide quantiﬁcation and is often
combined with different labelling methods on a cellular level
(Stable Isotope Labelling with Amino acids in Cell culture, SILAC),
protein level (Isotope Coded Protein Labelling, ICPL) or peptide
level (Isobaric Tag for Relative and Absolute Quantitation,
iTRAQ)[184]. Although superior in sensitivity, gel-free methods
rely almost exclusively on evaluating protein abundance as the
criteria for ﬁnding biomarkers; it is likely that many biomarkers
are post-translationally modiﬁed, and are therefore not being
identiﬁed in LC-MS/MS studies. For high throughput studies the
surface enhanced laser desorption/ionization time-of-ﬂight
(SELDI-TOF) technology remains a very promising approach with
clinical applications [185], but exactly what is detected is not clear.
4.5.3. Transcriptional and translational changes in cytokines
In addition to the Flt3-ligand mentioned above, studies
conducted during the last decade have provided additional
evidence of the involvement of cytokines in response to IR. These
low molecular weight glycoproteins are mainly produced by
immune cells and play a central role in the mediation and
regulation of immunity, through driving the development and
activation of immune cells, inﬂammation, and hematopoiesis
[186]. They are known to function in the form of networks and are
central players in cell-cell communication [186,187]. Cytokine
signalling pathways can activate a range of ﬁnal cellular impacts
including apoptosis, inhibitors of apoptosis, protein synthesis and
cell growth, and the inﬂammatory response. They can also
signiﬁcantly impact upon ROS generation and activation of
antioxidants (reviewed in Section 4.7.1). Interestingly, there is
also evidence that these pathways can impact upon damage
response signalling and/or DNA repair [188,189], processes
described elsewhere in this review.
Cytokines produced due to radiation-induced DNA damage are
thought to play a key role in the inﬂammatory reactions that are
associated with ionizing or UV radiation [190]. In general, they
cause a broad range of effects that are relatively tissue-speciﬁc.
They can impact on the microenvironment around the damaged
cell/tissue by affecting the surrounding stroma, epithelial compo-
sition and growth stimulation. TGFb for example acts via
autocrine, paracrine and endocrine mechanisms, and, depending
on the environment, can exert either tumour suppressor or tumour
promoter activity. Indeed TGFb orchestrates a complex network of
cellular response to radiation exposure functioning both as a
sensor and signal transducer of radiation induced stress. TGFbsignalling is efﬁciently activated after radiation exposure and
appears to be particularly important in regulating the normal
tissue response after radiation therapy [191,192].
At low dose and low dose rates of IR, cytokines play an important
role in the establishment of bystander effects (i.e. response of cells
that were not directly irradiated but were near irradiated cells or in
contact with irradiated cell medium). In a bystander cell model using
normal human lung ﬁbroblasts (HFL-1) and testing low doses of high
LET radiation, TGFb1 contributed to increase DSBs [193]. In a study
conducted by Ojima et al. (2008) [194], a supra-linear dose–
response was observed in normal human ﬁbroblasts irradiated with
doses from 1.2 to 200 mGy. This hypersensitivity was ascribed to
bystander effects. The mechanisms behind them were attributed to
ROS, nitric oxide and TGFb1. These factors are thought to be released
in the medium of irradiated cells and cause DSBs in non-irradiated
cells cultured in the same medium. However the dose/response
relationship of these changes is clearly complicated. IL6, IL8, MCP-1
and RANTES were identiﬁed in the growth medium of human dermal
ﬁbroblasts after exposure to 2 Gy and IL-6 was reported to promote
gH2AX foci formation whilst MCP-1 caused a drop in spot occupancy
(i.e. fraction of the nuclear area covered by gH2AX spots) [195].
Finally, microarray experiments using blood collected from donors
exposed to chronic low dose radiation following the Chernobyl
accident (range: 0.18–49 mSv during 11–13 years) showed a
transcriptional modulation of several cytokines including TNF-a/
b, IL-1b, IL-2, IL-10, IL-12b, chemokines (IL-8), macrophage colony-
stimulating factor (M-CSF), and apoptosis-inducing receptors [196].
Overall, these ﬁndings suggest that alterations in the transcrip-
tional proﬁle of certain cytokines might be suitable as biomarkers
of exposure to low dose radiation. However further validation,
including the validation of statistical methods used to analyze the
data from microarrays, is required to use them as such. The
speciﬁcity of such changes as a marker of radiation exposure, and
not just a marker of altered oxidative stress, needs to be fully
evaluated as well as the impact of confounding factors such as viral
infections, immune deﬁciency and age.
4.6. Biomarkers related to epigenomic modiﬁcations
Exposure to radiation has long been known to result in
epigenomic modiﬁcations which will affect gene regulation after
DNA damage induction. Through various check-points, epigenomic
modiﬁcations allow a very tight control of the amount of mRNAs
and proteins in the cell. First, the initiation of the transcription of
genomic DNA can be affected by the remodelling of the chromatin
structure via histone modiﬁcations. Second, given that transcrip-
tion regulation requires access of transcription factors for
activation or repression and splicing, DNA methylation may
compromise the transcription by preventing the binding of
transcription factors to the promoter region of the gene. Third,
additional check-points exist via miRNA which can bind to
transcribed mRNAs preventing their translation into proteins.
Other check-points exist also at the protein level (e.g. protein
phosphorylation), allowing a more speciﬁc functional modulation.
After DNA damage, post transcriptional regulation by miRNA
occurs at later time points than the fast (sec/min) but often
transient post-translational protein modiﬁcations, such as phos-
phorylation and ubiquitination, but before transcriptional regula-
tion changes (hours/days)[197]. The time-scales of these changes
and their stability will impact on their usefulness as biomarkers in
molecular epidemiological studies.
4.6.1. Histone modiﬁcations
Histones are considered as key players in epigenetics because of
their speciﬁc properties that can regulate gene expression
primarily by inﬂuencing the structure of the chromatin. Like most
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modiﬁcations, especially, but not exclusively, on their C-terminal
tails. At least eight different types of covalent histone modiﬁca-
tions (methylation, acetylation, phosphorylation, ubiquitination,
sumoylation, ADP ribosylation, deimination and proline isomeri-
zation) can occur and they often occur on different residues
simultaneously. Recently, no less than 51 distinct ‘‘chromatin
states’’ with different biological roles were identiﬁed in human T
lymphocytes based on the existence of speciﬁc combinations of
histone modiﬁcations [198,199]. The changes in the proﬁle of these
modiﬁcations in response to IR are likely to be dose- and time-
dependent and whether the various modiﬁcations are inter-related
or mutually exclusive, remains to be fully established.
The function of histone modiﬁcations is exerted mainly through
two distinct mechanisms: inﬂuencing the overall structure of the
chromatin, which can occur over short or long distances, or by
modulating the binding of effector molecules [200]. The effects of
histone modiﬁcations have implications not only for gene
transcription, but also for DNA repair, replication and recombina-
tion.
Probably the best known histone modiﬁcation that occurs in
response to radiation-induced DNA damage is the phosphorylation
of the serine-139 residue of histone H2AX (gH2AX) near the site of
the damage. The use of gH2AX as a biomarker of DNA DSBs has
been discussed in Section 4.2.2. The main mechanisms by which
histone modiﬁcations inﬂuence DNA repair are via the recruitment
of DSB repair factors, as in the case of phosphorylation or
sumoylation of histones, or by modifying the chromatin structure
to render the DNA more or less accessible to the DNA repair
machinery. In general, methylation of histones, which occurs
mainly on lysine and arginine residues, leads to a more compact
conformation of the chromatin, making the DNA less accessible to
transcription factors but also less accessible to DNA repair factors.
Recent studies have shown that methylation of several histone
residues is induced by high doses of IR but the IR speciﬁcity of such
changes is not well described [201,202]. Acetylation of histone
tails, which is regulated by histone acetyltransferases (HATs) and
histone deacetylases (HDACs), mainly renders the DNA more
accessible to the transcription machinery and therefore promotes
transcriptionally active euchromatin. However, changes in chro-
matin conformation also affect the accessibility to other proteins
with a DNA-based function such as DNA repair proteins and several
lines of evidence have demonstrated that histone acetylation of
different histone residues (e.g. H4K16 and H3K56) plays an
important role in modulating DNA damage repair mechanisms
induced by moderate to high doses of IR [203,204].
Overall, the published literature on the effects of irradiation on
methylation, acetylation, ubiquitination and other post-transla-
tional modiﬁcations of histones almost exclusively reports studies
that have investigated the effects of high doses using in vitro
models ([200,202,204–209] and Supplementary Data B) and
clearly not all the players in these processes have yet been fully
characterised and others probably remain to be identiﬁed. It is
clear that further studies are needed before assessing whether
these epigenomic changes can serve as possible biomarkers for
epidemiological studies on the effects of low dose exposure to IR in
humans. In particular, for use as biomarkers of exposure, the
relationship between the doses received and the proﬁle and extent
of histone modiﬁcation and its persistence need to be established,
as well as the speciﬁcity of any changes in terms of the spectra of
agents that will induce the modiﬁcations. It is possible that, as for
gH2AX, a limited persistence of the signal after irradiation and the
fact that several types of DNA damaging agents can produce the
modiﬁcation, will make them unsuitable for retrospective studies
but they may prove to be useful biomarkers of susceptibility or
persistent effects. Signiﬁcant advances in understanding theeffects of IR on epigenetic states are required before fully validated
biomarkers become available.
4.6.2. DNA methylation
DNA methylation consists of the covalent addition of a methyl
group (–CH3) to a cytosine, mainly in a CpG dinucleotide. This
heritable DNA modiﬁcation induces a local change in the
chromatin structure which ultimately leads to the modulation
of transcription, most frequently repression. DNA methylation is a
key component in the control of gene expression in speciﬁc tissues
and the germline and its involvement in carcinogenesis is well
known [210,211]. Several studies have shown that exposure to IR
can lead to both hypo- and hypermethylation [210,212,213]. Low-
dose radiation can regulate DNA methylation, which in turn can
affect low-dose radiation responses such as bystander effects or
genomic instability [214].
However, given the variability of the results of studies on the
methylation status of DNA after irradiation, in particular at low-
dose ranges, it is unlikely that currently DNA methylation would be
a suitable biomarker of exposure, effect or susceptibility in an
epidemiological molecular study addressing the effects of radia-
tion exposure. Further studies are needed to conﬁrm at least the
changes induced by different doses and/or radiation quality of
irradiation and the impact of this change (hypo- or hypermethyla-
tion) on gene expression, as well as the effect of confounding
factors such as age and other exposures. Recent technological
advances such as Methyl-CpG binding domain protein sequencing
(MBD-seq) that is widely used to survey DNA methylation patterns
should help resolve these issues [215]. In addition based on
promising results in the cancer detection ﬁeld, the possibility of
measuring the methylation pattern of candidate genes in biological
samples as a biomarker of cancer risk needs to be fully evaluated
[216,217].
4.6.3. miRNA
miRNA are small (around 22 nucleotides) highly conserved
non-coding RNAs that bind to mRNA and promote mRNA
degradation or altered translation. They are involved in post-
transcriptional regulation of gene expression and play a role in
numerous physiologic processes in normal and malignant cells.
The efﬁciency of miRNA-mRNA pairing, and consequently gene
expression levels, can be affected by miRNA levels and also by SNPs
(see also Section 4.3.1) in miRNA genes as well as SNPs located in
miRNA binding sites of mRNA 30UTRs [218]. MiRNA expression
proﬁles are very tissue speciﬁc and tumours show highly speciﬁc
expression signatures which can be correlated with tumour state
and tumour prognosis [219,220]. There are many recent studies
that have shown that their expression proﬁles can be modulated
following exposure to both low and high LET irradiations and it has
been suggested that these miRNA expression signatures can be
used as biomarkers of radiation exposure (see recent reviews
[197,210,214]). Templin et al. reported that 4 h after in vivo
exposure of radiotherapy patients to 1.25 Gy of IR an upregulation
of the expression of a considerable proportion of the human
miRNAome of peripheral blood cells was detected [221]. Interest-
ingly, among all the genes controlled by miRNAs under these
experimental conditions, they found that biological processes such
as hemopoiesis and the immune response were targeted by miRNA
control whereas metabolic processes were under-represented. In
contrast Aypar et al. showed that in GM10115 cells only three
miRNA involved in two major pathways were altered after high LET
irradiations while six miRNA involved in ﬁve major pathways were
altered after low LET irradiations [213]. A number of DNA damage
responsive miRNAs that regulate many cellular processes and
pathways have been described [197]. For instance the miRNA-138
modulates DNA damage responses by repressing histone H2AX
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as a biomarker of the formation of DNA DSB; see Section 4.2.2).
However as discussed by Woulters et al., it is hard to extract
common miRNA responses from such studies since different
microarray platforms, types of radiation, doses and dose-rates
have been used, which may all inﬂuence outcome [197]. In
addition, as miRNA levels are themselves modulated both by
genetic and epigenetic alterations, a complex interplay exists
between the miRNAs and their targets which appears to be cell
type speciﬁc. The use of the expression proﬁle of miRNAs as
biomarkers is very much in the developmental stages and clearly
more information on sensitivity, speciﬁcity to IR, the timing of
expression changes after exposure and the biological material in
which such changes can be measured is necessary.
4.6.4. Phosphoproteome
Of the post-translational modiﬁcations, phosphorylation is
essential in signal transduction, gene regulation, and metabolic
control in cells, especially in response to intracellular and
extracellular changes and stimuli. Therefore the identiﬁcation of
phosphoproteins, which phosphorylation sites regulate protein
function, and the upstream signalling kinases involved in this
modiﬁcation will provide valuable insight into the molecular
mechanisms that regulate the cellular responses to IR. The analysis
of the phosphoproteome can be achieved by using immunohisto-
chemical based techniques such as reverse phase protein arrays
that typically characterise one phosphoprotein, and often only one
speciﬁc phosphorylation site, at a time. Such techniques are
hampered by the availability of validated antibodies, tissue
handling variability, and intratumoral heterogeneity. However,
in the clinical setting this technique has shown great promise by,
for instance, identifying dysregulated signalling pathways in
tumours, providing insight into patient-speciﬁc differences that
may impact on clinical outcome [223,224]. Recent technological
advances in LC-MS technology now also enable the broad
proteome-wide study of phosphorylation (phosphoproteomics)
and allow the identiﬁcation of thousands of phosphorylation sites
(and often multiple sites in an individual protein) in a particular
proteome; such an approach has been used to examine the
phosphoproteome of primary human skin ﬁbroblasts 1 h after
exposure to 20 and 500 mGy [225]. Phosphorylation sites on
proteins such as TP53BP1 but also on previously unidentiﬁed
radiation-responsive proteins such as the candidate tumor
suppressor SASH1 were identiﬁed [225]. Those results show the
potential of such an analysis to identify radiation-induced post-
translational modiﬁcation but in terms of validation for use of a
biomarker of any category many questions remain and their
applicability to biological samples collected in a molecular
epidemiological setting will need validating.
4.7. Other biomarkers
4.7.1. Reactive oxygen species
ROS are molecules or ions, such as superoxide, peroxide or
hydroxyl radicals that result from the interaction of an electron
with an oxygen molecule. IR can lead directly to their production,
creating directly induced (or targeted) DNA damage or damages to
the nucleotide pool as mentioned in Section 4.2.3. However, a
plethora of evidence has shown that IR can also lead to the
activation of ROS indirectly via a range of signalling processes,
release of ROS from the mitochondria or changes to the cell’s
microenvironment, including the activation of an inﬂammatory
response. Frequently, the antioxidant capacity of a cell adapts to
ROS levels change, so that the steady state level of ROS and/or ROS
damage is minimised. If we deﬁne oxidative stress as a situation
where the generation of ROS exceeds the antioxidant capacity of acell, then IR can also lead to oxidative stress. Furthermore,
oxidative stress itself can lead to a situation where ROS levels
increase, further confounding the situation. In addition to ROS,
reactive nitrogen species such as peroxynitrite anions (ONOO)
can form through interaction of nitric oxide with superoxide
anions.
The precise signal that initiates stress response signalling is
unclear. However, there is evidence that extranuclear targets can
mediate genotoxic effects of radiation. The bystander response
(also brieﬂy discussed in Section 4.5.3) demonstrates that
signalling can be relayed from a damaged cell to an undamaged
cell, demonstrating that the target might be extracellular.
Additionally, oxidants, as well as other free radicals, can react
with lipids, proteins and DNA. For example, lipid peroxyl radicals
and their decomposition products and intermediates of lipid
peroxidation can lead to the generation of reactive aldehydes
including 4-hydroxynonenal (4-HNE). In general, ROS are short
lived and therefore not suitable as a biomarker but there are
examples where elevated ROS production can be maintained for
some considerable time after radiation exposure, and elevated
levels of ROS have been reported after IR. Assays to monitor ROS
levels are unlikely to be useful for biomonitoring purposes due to
the short half life of ROS and the fact that the response is not
speciﬁc to radiation exposure. The products of ROS damage, such as
protein and lipid oxidation products have the potential to be
exploited as biomarkers. Some possible products are listed in
Supplementary Data C. However, as for monitoring ROS levels,
there is likely to be a lack of speciﬁcity for IR. A recent review has
considered the range of oxidatively generated base damage to
cellular DNA and considered procedures to measure such damage
[226]. Again, however, this is unlikely to have major application for
biomonitoring purposes due to their short half life. The activation
of antioxidant levels can represent a potential biomarker although
again such activation can be transient. Further, the tentative
biomarkers of oxidative stress listed in Supplementary Data C need
with a few exceptions to be further characterized regarding dose–
response relations, persistence in time and speciﬁcity. As reviewed
above most of these biomarkers are likely to be induced by several
types of stressors. A possible route to improve the situation is to
combine a set of these biomarkers.
4.7.2. Metabolites and metabolomics
Metabolomics is a recent ‘‘omics’’ technology that focuses on
the study of metabolites, which are usually deﬁned as small
molecules with a mass less than 1 kDa. Although not exhaustive,
many metabolite databases – e.g. Human Metabolome database
(http://www.hmdb.ca/), Madison Metabolomics Consortium Da-
tabase (http://mmcd.nmrfam.wisc.edu/), METLIN Metabolite Da-
tabase (http://metlin.scripps.edu/) – are available [227].
Metabolomics methodologies which mainly involve chromatogra-
phy and mass spectrometry-based techniques, have been recently
reviewed elsewhere [228]. Because metabolites result from the
interactions between several complex cellular networks, metabo-
lomics can provide a qualitative and quantitative overview of the
global perturbations induced by IR in cells and biological ﬂuids. In
fact, many of the urinary metabolites observed speciﬁcally
following radiation exposure represent products resulting from
oxidative stress. Studies in rodents using metabolomics have
shown an increase of purine and pyrimidine derivatives, such as 20-
deoxyuridine and thymidine, in urine after an exposure of 1–3 Gy
of g rays [229–231]. In humans, a study performed on patients who
underwent a 131I-therapy observed an increase of salivary
isoprostaglandins, whereas no increase in isoprostane levels in
urine was observed in a study of patients treated for prostate
cancer [232,233]. By testing the entire metabolome without
focusing on a particular metabolite, metabolomics might detect
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in an epidemiological study. However, currently, there is no
evidence that the metabolomics technology is sensitive enough to
detect metabolite modulations after low dose radiation in humans.
4.7.3. Biomarkers associated with cell cycle delay, apoptosis and cell
survival
The cell cycle is composed of the G1 phase (cell growth), the S
phase (replication of the DNA), the G2 phase (preparation to
divide) and the mitotic phase (cell division). Exposure to radiation
is known to lead to delays in the progression through this cycle and
to impact on cell survival; a number of bioassays based on these
endpoints have been used to assess radiosensitivity.
A modest radiosensitivity in heterozygous carriers of mutations
in the ATM gene was identiﬁed using a radiation-induced G2 phase
cell cycle delay assay in lymphoblastoid cells [234]. A similar assay
performed on lymphoblastoid cells (3 Gy) identiﬁed a radiosensi-
tive sub-group within breast cancer patients [235]. The association
between abnormal radiation-induced cell cycle delay and breast
cancer cases has also been conﬁrmed in other studies, although
opposite results regarding the direction of changes (reduced or
prolonged) in cell cycle delay for cancer patients were reported
[236,237]. Finally, several studies, including case-control studies,
performed on lymphocytes or lymphoblastoid cells from lung
cancer patients have showed a reduced cell cycle delay after
irradiation with 1–2.5 Gy [238–240]. Inter-individual variation in
radiation-induced cell cycle delay, radiation-induced apoptosis
and human population variation in the expression of certain DNA
repair, cell cycle and apoptosis genes has been shown to have a
signiﬁcant heritable component [241–243].
Regarding apoptosis, signiﬁcantly reduced apoptotic responses
increasing with age have been observed in breast cancer patient’s
lymphocytes irradiated with 4 Gy [244] although another study
reported an increased radiation-induced apoptotic responses in
breast cancer cases’ lymphocytes after 5 Gy [237]. A very low
induction of apoptosis in AT homozygotes together with a reduced
level in AT heterozygotes and in breast cancer patients compared
to normal individuals was also observed in a study where
lymphocytes were exposed to 4 Gy [245].
Skin ﬁbroblast clonogenic cell survival assays has been used to
test in vitro radiosensitivity in recurrence-free breast cancer
patients [246]. However the difﬁculty associated with obtaining
ﬁbroblasts from subjects and the time needed to complete the
assay (2–3 months) would severely limit the use of such bioassay
in a large-scale molecular epidemiological studies.
In summary, it is clear that there is signiﬁcant inter-individual
variation in cell cycle and apoptotic responses following radiation
exposure. Bioassays based on these cellular endpoints hold
promise as biomarkers of radiation sensitivity. However the data
available are not entirely consistent, responses to low dose
radiation exposure are poorly characterized and it is likely that
some of the assays are very sensitive to experimental conditions.
Therefore, further validation will be needed before considering cell
cycle delay and apoptosis as biomarkers of IR in large scale
epidemiological studies including the careful evaluation of
potential confounding factors such as age, smoking status, and
ethnicity.
4.7.4. Biophysical markers
The concentration of radicals that are formed by IR and that
persist for a sufﬁciently long time in solid biological materials such
as bones, tooth enamel, ﬁnger nails and hair can be measured by
electron paramagnetic resonance (EPR or alternatively ESR)
spectroscopy. EPR dosimetry is a non-destructive spectroscopic
technique based on the correlation between the intensity or
amplitude of the radiation-induced signals with the dose absorbedfor instance in the tooth enamel [247]. A number of potential
confounding factors have been identiﬁed such as UV exposure and
the health status of the teeth (see [247] for an extensive review).
The invasive sampling necessary to obtain teeth and bones limits
the application of this technique to retrospective dosimetry.
However several groups are investigating alternative non-invasive
methodology that measure non organic radicals. For instance
Trompier F, et al. [248] have investigated the potential of carrying
out EPR spectrometry on the plastics that can be found in personal
effects such as glasses (CR-39, polycarbonate), mobile phones
(PMMA, polycarbonate), watches and buttons, although signal
fading would appear to be a limitation for the use of such an
approach in epidemiological studies and these personal items
should have been in use for many years to provide relevant
information about past exposure. In addition transportable EPR
spectrometers, developed to facilitate tooth dosimetry in an
emergency response setting, have been developed which allow the
upper incisors to be used as a dosimeter (see for instance [249]).
However the lower limits of detection could be a limiting factor
outside an emergency setting where EPR tooth dosimetry is likely
to be a valuable resource for triage following potential radiation
exposure of a large population.
4.8. Biological determination of exposure/intake of internal emitters
Due to the nature of emitted radiations and to the biokinetics of
dose distribution from internally incorporated radionuclides,
estimation of dose from internal emitters poses particular
challenges and biological monitoring has long been used in
occupational, medical and accidental settings to provide a
qualitative indication of exposure or a quantitative assessment
of absorbed dose to a speciﬁc organ or tissue over a speciﬁc time
period.
The body content of radionuclides can be measured directly in
vivo using detectors set outside the body. The energy spectrum
indicates the isotopic composition, while the counting rate is
converted into activity through calibration with anthropomorphic
phantoms. Such techniques provide a quick and convenient
estimate of activities in the body or in a speciﬁc organ such as
the thyroid for iodine or the lung for insoluble aerosols. This,
especially when carried out with dedicated mobile units, is the best
measurement technique immediately after a major accident when
multiple measurements have to be performed (for example
cohorts of children with measured thyroid activity have been
established and followed in Belarus and Ukraine [250,251] and
extensive measurements have been made in the regions most
affected by the Fukushima accident in Japan) in the same area over
a short period of time, and for the monitoring of short lived
radionuclides such as radiopharmaceuticals used in nuclear
medicine. However this approach is feasible only for radionuclides
emitting radiation that can ‘‘escape from’’ the body: X-rays, g or
energetic b particles but not pure a or low energy b emitters.
In vitro or indirect measurement involves the analysis of
excreta or other biological samples (nose blow, nasal smear, saliva,
blood or biopsy). This is the only measurement approach for
radionuclides which emit no penetrating radiation. Periodic
excreta (in particular urine) measurements have been widely
used since the 1950s to monitor intake of radionuclides in
occupational settings because of their high sensitivity and
applicability to any radionuclide. Retrospective individual dose
reconstruction has been conducted from historical urine measure-
ments in several epidemiological studies, including the case-
control study of lung cancer and leukaemia risk in Belgium, French
and UK uranium and plutonium workers in Alpha-Risk [252,253],
studies of plutonium workers at the Mayak Production Association
[254], of tritium exposure in CANDU reactors in Canada [255] and
Table 5
Temporal classiﬁcation of IR biomarkers.
Biological classiﬁcation of IR biomarkers Temporal classiﬁcation of IR biomarkers
Exposure Susceptibility Late effects Persistent effects
Cytogenetics Dicentrics H P Pa P
Translocations H P Pa H
CCR H (high LET IR) P Pa H
PCC rings and fragments H
Telomere length P P Pa P
Micronuclei H P Pa
Nucleotide pool damage
and DNA damage
SSB/DSB H P
g-H2AX H P P P
Extracellular 8-oxo-dG (oxidative stress) P
Germline inherited
mutations/variants and
induced mutations
SNP, CNV and inherited
gene mutations
H P (minisatellites
in offspring)
P
CNA P P
GYPA H H
HPRT H H
Transcriptional and
translational changes
Changes in the mRNA levels
of the ATM/CHK2/p53 pathway
H P
Changes in RNAs identiﬁed by
transcriptomics
H P P P
Serum amylase H
CRP H H
Proteins identiﬁed by proteomics P P P P
Cytokines P P P P
Epigenomic modiﬁcations Histone modiﬁcations P P P P
DNA methylation P P P P
miRNA H P P P
Phosphoproteomics P P
Other biomarkers ROS H P P P
Metabolites and metabolomic H P P P
Cell cycle delay, apoptosis and survival P P
Direct dosimetry on samples EPR/ESR H H
Internal emitters H
H: direct evidence that this biomarker could be used as such; P: potential or theoretical use; CCR: complex chromosomal rearrangement; CNA: copy number alteration; CNV:
copy number variant; CRP: c-reactive protein; DSB: double strand break; EPR/ESR: electron paramagnetic resonance/electron spin resonance; GYPA: glycophorin A; HPRT:
hypoxanthine-guanine-phosphoribosyl transferase; IR: ionizing radiation; miRNA: microRNA; PCC: premature chromosome condensation; SNP: single nucleotide
polymorphism; SSB: single strand break; ROS: reactive oxygen species.
a Chromosomal aberrations due to genomic instability.
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exposure among Rocketdyne/Atomics International workers in the
USA [257].
Individual in vivo or in vitro measurement of radionuclide
emissions provides direct evidence of exposure. However,
measurement results only provide point information on the
contamination at a given time. Models, combined with scenarios
of exposure including the assumed rate of exposure and the
physico-chemical nature of the incorporated material, have to be
applied to evaluate the individual intake and dose and to
quantitatively assess exposure. If the measurement is performed
reasonably soon after intake and if the mode of intake, chemical
form of the nuclide and solubility are known, the typical detection
limit allows the assessment of doses down to 1 mSv and even
below in some situations. Generally for all measurement
techniques, the sensitivity in terms of dose assessment decreases
with time after exposure due to radioactive decay and biological
clearance. The precision of the assessed dose strongly relies,
however, on the information available on the exposure (assessed
doses can vary by an order of magnitude or more for Pu depending
on solubility) and individual physiology as well as on the number
and combination of measurement data on individuals. In the case
of chronic exposure, the sensitivity and quality of the dose
reconstruction will depend directly on the timing of measure-
ments. The frequency of measurement should be consistent withthe radionuclide involved: while a yearly measurement of long-
lived and strongly retained plutonium would allow a reasonable
estimate of dose, a dose assessment for short-lived radiopharma-
ceuticals would require daily to monthly measurement [258].
5. Discussion
5.1. Potential use of biomarkers for epidemiological studies
As reviewed above (Tables 1–4) and summarised in Table 5,
there are a number of endpoints that can be assessed in an
epidemiological setting using biological samples that could be
obtained from a large proportion of a study population with
relative ease, and that show potential in one or more of the four
categories of biomarkers discussed above: biomarkers of exposure,
of susceptibility, of persistent effects and/or of late effects. At this
time, the best established and validated markers, at moderate and
high doses, are biomarkers of exposure measured shortly after
irradiation. There is a need to validate potential biomarkers of
exposure, susceptibility, and late and persistent effects at low
doses.
As shown in Table 5, some biomarkers may ﬁt in more than one
category, depending on the timing of biological sampling. As
discussed above, most potential biomarkers (as is the case for
biomarkers of other types of exogenous and endogenous exposures
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confounding. In addition, with the possible exception of dicentric
chromosomal aberrations and of in vivo or in vitro measurement of
radiation from internally incorporated radionuclides, it appears
unlikely, at present, that biomarkers will be found in the near
future that provide an indisputable signature of radiation effects:
biomarkers with 100% speciﬁcity (only present in case of radiation
exposure) and 100% sensitivity (always present in case of radiation
exposure).
Nevertheless, what can be gained from the identiﬁcation of
biomarkers (the gain of molecular epidemiology compared to
‘‘classical’’ epidemiology) is an improvement in the quantiﬁcation
of the relationship between radiation exposure and late effects.
Compared to already available dosimetric information, exposure
biomarkers should allow a better classiﬁcation of individuals by
level of exposure or dose, whereas effect biomarkers should allow a
better classiﬁcation of potentially diseased and healthy individua-
ls. The information provided by biomarkers should help in
reducing biases due to misclassiﬁcation, and therefore, should
allow a more precise estimation of the exposure-risk relationship.
Also, the identiﬁcation of biomarkers of susceptibility should
facilitate analyses on more homogeneous populations and provide
more precise estimations of the exposure-risk relationship in
different population subgroups, reducing selection biases and
providing information on the variability of risks between
individuals, which has important implications for radiation
protection particularly in medical and occupational settings.
Serious consideration should therefore be given to the
integration of epidemiology and biology through the exploitation
of existing samples in epidemiological studies and the joint
planning of future molecular epidemiological studies, with careful
collection and processing of samples, and for future analyses of
biomarkers that will provide answers to key questions in radiation
protection research. The identiﬁcation of predictive biomarkers
suitable for large scale analysis requires the investigation of
cellular mechanisms that control the cellular and tissue response
to low doses of radiation and that thus confer sensitivity. Finding
biomarkers of relevance to mechanism identiﬁcation may require
growth or analysis of cells, including cell lines, that may not be
suitable for use as a predictive biomarker of susceptibility but
could be of use for a limited subset of people, for example in the
framework of nested case-control studies of speciﬁc diseases.
5.2. Possible limitations of molecular epidemiology studies
As in classical epidemiological studies, potential limitations of
molecular epidemiological studies concern confounding, bias and
random error [259]. Typical confounders or risk modiﬁers are age,
gender and ethnicity. Cancer-related potential confounders
include smoking status, exposure to occupational carcinogens,
medical treatment, other sources of exposure to IR, and factors
related to cardiovascular diseases (i.e. blood pressure, weight,
cholesterol, etc.). If no or limited information on such factors is
available or confounders are not adequately controlled for in the
statistical analyses, confounding cannot be excluded. Uncertainty
in the assessment of radiation exposure or dosimetry as well as
inaccuracy in the determination of the disease or biomarker under
investigation could also lead to bias. Particularly the use of
validated biomarkers is an important issue in molecular epidemi-
ological studies.
Most of the published molecular epidemiological studies of low
dose radiation effects are small-scaled and suffer from low
statistical power. Sufﬁcient statistical power is an essential
criterion for an informative study to detect an association of a
biomarker with either radiation exposure, persistent or late
radiation induced effects or genetic susceptibility, if present.Moreover possible interaction of these biomarkers with other
biomarkers or risk modiﬁers may require even larger studies. The
statistical power is determined by several factors such as the study
size, the range of radiation exposure, the number of cases and
duration of follow-up, but also the ratio of intra-individual
variation to inter-individual variation of a biomarker. If the
expected effect of a relationship or difference is small, as it may be
in the ﬁeld of radiation research focussing on the low dose range,
very large studies are necessary to detect these effects if they exist.
Presently, a large number of ‘‘classical’’ epidemiological studies
on IR and cancer exist [260]. Most of these studies deal with the
relationship between radiation exposure and cancer risk. The
number of studies is appreciably lower for studies on radiation
induced non-cancer effects such as cardiovascular diseases or on
the late effects of internal contaminations. Most studies are based
on either medically (diagnostic or therapeutic), occupationally (e.g.
nuclear worker, uranium miner, Mayak worker, Chernobyl
liquidators) or environmentally (Mayak, Chernobyl residents,
etc.) radiation exposed groups [260]. They differ with respect to
type of radiation such as external radiation or internal exposure
(plutonium, radon, uranium, etc.) and thus involve different
pathways and different radiation related diseases.
A recent review of these studies by some of the co-authors
(Pernot et al. in preparation), demonstrated that currently only a
limited number of studies have collected and stored biological
samples – generally only at one point in time – and that samples
may be available only for relatively small proportions of the
cohorts, thus limiting the statistical power of the studies. Further,
validation of sample collection and storage is needed to ensure that
stored samples can be used for analysis of speciﬁc biomarkers.
Generally prospective studies have advantages in comparison
to retrospective studies because biological samples and dosimetric
information are collected before disease of onset, and there is the
possibility of getting repeated measurements and biological
samples over time. In contrast to this, retrospective studies, in
which exposure may have taken place a long time ago, would
involve collecting biological samples many years after exposure,
and in case-control studies, after the cases have developed the
disease of interest—thus possibly affecting the results of the
biomarker analyses. Prospective follow-up is useful to study
biomarker of exposure, susceptibility and early and late effects as
well as their evolution over time. However, starting now
prospectively new large molecular epidemiological studies may
involve a long duration before the occurrence of the disease under
investigation and will involve considerable costs. A much less time
and resource consuming approach would be to conduct nested
case-control studies within large scale epidemiological cohorts
and collect biological samples and reconstruct doses only on cases
of the disease of interest and on a limited number of controls. This
could reduce the number of subjects (and in parallel study costs)
from hundreds of thousands to several hundreds. It would allow
the investigation of biomarkers of susceptibility and biomarker of
persistent effects and provide important opportunities for
biomarker validation.
Another method to overcome the limitation of insufﬁcient
power in molecular epidemiological studies is pooling of these
studies to increase the study size and the precision of risk
estimates. In contrast to meta-analyses, pooled studies use the
original individual data, which allow interaction tests and sub-
group analyses including dose–response relationships to be
performed [261]. However, pooled studies require standardized
data on exposure, disease, potential confounders and effect
modiﬁers; and standardized methods for collection and storage
of biomarkers to avoid heterogeneity between studies. Next to
that, different ethical and data safety rules across the laboratories
and countries have to be considered. The legal requirements
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more complex than those for classical epidemiological studies and
can be particularly complex for retrospective sample collection.
Informed consent from all study participants should be available in
order to use the biological data for future study questions and by
other researchers.
Overall, the major limitations in conducting large molecular
epidemiological studies are the costs, the accessibility to biological
samples, the participation rate of subjects, and logistical difﬁcul-
ties in recruiting sufﬁciently large number of subjects. In addition,
very strict ethical and data safety protection rules could hamper
the establishment of molecular epidemiological studies and
biobanks as discussed in Section 3.2.
5.3. Can biomarkers provide insight into the shape of the dose–
response curve?
One of the goals of molecular epidemiological studies consid-
ered in this manuscript is to deﬁne the shape of the dose response
for radiation induced health effects (for example cancer or
cardiovascular disease) following low doses of radiation exposure
in order to optimise guidelines governing radiation protection.
While the study of the dose-response of speciﬁc biomarkers is
essential, it should be noted that biomarker yield may not be
synonymous with health effect. Some biomarker responses appear
to be linear with dose, while others are not. For example, it has
been shown that G2/M checkpoint arrest has a deﬁned threshold
for its activation, that DSB repair may not function efﬁciently at
low doses and that the bystander effect reaches a plateau after low
doses [127,128,262]. For most biomarkers directly related to DNA
damage, linear dose–response relationships apply at short times
after exposure. In contrast, for biomarkers more dependent on
cellular processing of direct damage, more complex linear-
quadratic and other relationships may be observed. Thus, the
dose-response for a particular health effect (for example cancer
induction) is at present difﬁcult to evaluate as it may be the result
of a number of parallel processes (DNA damage, repair, epigenetic
effects, tissue interaction effects, etc.) which might have different
dose-responses. It is therefore essential to study not only the dose-
response in the context of speciﬁc bioassays but to gain insights
into the shape of the dose–response curve for health effects, by
interfacing molecular analysis with epidemiological studies.
6. Conclusions
When considering suitable biomarkers of IR for use in large
scale epidemiological studies, criteria such as sensitivity (in
particular for low dose exposure), speciﬁcity to IR, persistence,
availability of biological samples, technical applicability to large
scale and cost should be taken into account. These requirements
considerably reduce the number of possible candidates and
explain why, currently, there is no ideal biomarker for assessing
exposure, effect or susceptibility of low dose radiation exposure.
There are some good validated biomarkers for acute radiation
exposure to doses above 100 mGy (e.g. dicentrics) but not for lower
doses, although some good candidates do exist (e.g. gH2AX) (Table
5). Likewise, there is currently no suitable biomarker of radiation
susceptibility after low dose exposures. However, there is clearly
the potential to identify suitable genetic biomarkers of suscepti-
bility as large cohorts of exposed individuals do exist which could
be used to for instance for GWAS. Technological developments and
reduction in their costs will probably help the evaluation of genetic
variations (SNPs and CNV) but extrapolating this information for
the development and validation of any kind of biomarker is going
to be for the future. More generally, the -omics ﬁelds are fast
moving and such studies may identify endpoints that can be usedfor different classes of biomarkers. Many of the tests based on
transcriptomics methods are criticised and challenged on their
ability to predict disease risk over long periods of time. At least one
study provides some reason for optimism that transcriptional
responses bear a relationship to lifetime disease risk [146].
However further validation of -omics endpoints is required to
ensure their speciﬁcity to IR and their usefulness as biomarkers of
exposure and susceptibility.
Because multiple end points and tissues are involved in the
responses to low dose radiation, a multi-marker approach will
provide information about the interplay of different possible
pathways and will be needed to evaluate an individual’s risk. An
unbiased multiparametric approach will be needed to identify
novel biomarkers [263].
Ultimately, the integration of biology with epidemiology
requires careful planning and enhanced discussion among the
epidemiology, biology, and dosimetry communities. This will serve
to determine the most important questions to be addressed, the
appropriate study design and population to be investigated (either
occupationally, environmentally or medically exposed). Also
essential are the logistics of biological sample collection, proces-
sing and storing and the choice of biomarker or bioassay, as well as
awareness of potential confounding factors.
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